<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006140.pub2" GROUP_ID="ADDICTN" ID="622206010411561168" MERGED_FROM="" MODIFIED="2008-03-27 16:15:22 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Synopsis?&lt;br&gt;Heroin dependence is considered a chronic lifelong relapsing disease with several treatment options consisting of two major categories: non-pharmacological based interventions and maintenance therapy with agonists (e.g. methadone) or antagonists (e.g. naltrexone).&lt;br&gt;An increasing number of opioid dependent patients in countries like the USA, UK and Australia are treated with novel naltrexone sustained-release formulations. To the best of our knowledge, however, no such preparation is fully approved by any national medical agency nor is its clinical effectiveness evaluated in any systematic review. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-03-27 16:13:46 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="42" REVMAN_SUB_VERSION="5.0.0" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-03-27 16:15:22 +0100" MODIFIED_BY="Laura Amato">
<TITLE>Sustained-Release Naltrexone For Opioid Dependence</TITLE>
<CONTACT>
<PERSON ID="DD5A28E582E26AA201E74FE90AD7CE2A" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Philipp</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lobmaier</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>p.p.lobmaier@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Norvegian Centre for Addiction Research</DEPARTMENT>
<ORGANISATION>University of Oslo,</ORGANISATION>
<ADDRESS_1>Kirkeveien 166</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oslo</CITY>
<ZIP>0407</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+47 - 23 36 89 38</PHONE_1>
<PHONE_2/>
<FAX_1>+47 23368901</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-03-27 15:04:21 +0100" MODIFIED_BY="[Empty name]">
<PERSON ID="DD5A28E582E26AA201E74FE90AD7CE2A" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Philipp</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lobmaier</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>p.p.lobmaier@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Norvegian Centre for Addiction Research</DEPARTMENT>
<ORGANISATION>University of Oslo,</ORGANISATION>
<ADDRESS_1>Kirkeveien 166</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oslo</CITY>
<ZIP>0407</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+47 - 23 36 89 38</PHONE_1>
<PHONE_2/>
<FAX_1>+47 23368901</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1B30D18882E26AA201A256C77BE20265" MODIFIED="2008-03-27 15:04:21 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Hege</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kornor</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Adviser</POSITION>
<EMAIL_1>hege.kornor@nokc.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+47 41225577</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Norvegian Knowlege Centre</DEPARTMENT>
<ORGANISATION>Health Services</ORGANISATION>
<ADDRESS_1>PO Box 7004, St Olavsplass</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oslo</CITY>
<ZIP>0130</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+47 23255067</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1B38BC1582E26AA201A256C79F5ABE30" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Nikolaj</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kunoe</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow</POSITION>
<EMAIL_1>nokolaj.kunoe@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unit of Addiction Medicine</DEPARTMENT>
<ORGANISATION>University of Oslo</ORGANISATION>
<ADDRESS_1>Kirkeveien 166</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oslo</CITY>
<ZIP>0407</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+47 23368930</PHONE_1>
<PHONE_2/>
<FAX_1>+47 23368901</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18411" MODIFIED="2008-03-27 15:03:38 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Arild</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bjørndal</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>arild.bjorndal@kunnskapssenteret.no</EMAIL_1>
<EMAIL_2>arb@shdir.no</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Norwegian Health Services Research Centre</ORGANISATION>
<ADDRESS_1>Postbox 7004</ADDRESS_1>
<ADDRESS_2>St. Olavs plass</ADDRESS_2>
<CITY>Oslo</CITY>
<ZIP>0031</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+47 23 25 50 24</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-03-27 16:15:22 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Minor update: 13/11/07&lt;/p&gt;" NOTES_MODIFIED="2008-03-27 14:57:39 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="25" MONTH="1" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="27" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Unit for Addiction Medicine, University of Oslo</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Norwegian Knowledge Centre for the Health Services</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-03-27 16:05:07 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>People with opioid dependence require substantial therapeutic effort to keep them drug free. Their use of illicit opioids can be reduced and retention in treatment improved with supervised agonist replacement therapy with</TITLE>
<SUMMARY_BODY>
<P>methadone, which is a highly addictive drug. Naltrexone is a long-acting, opioid-antagonist that blocks heroin effects. It is used to prevent relapse of both opioid and alcohol dependence. Highly motivated people do best with <BR/>naltrexone. Most opioid users are sceptical about treatment with naltrexone tablets and many drop out early on. Dropouts can be reduced with supervised tablet taking, offering incentives and using sustained-release naltrexone <BR/>such as subcutaneous implants or depot injections.<BR/>There is insufficient evidence from randomised controlled trials to evaluate the effectiveness of sustained-release naltrexone. In the one controlled study that met inclusion criteria, 60 outpatients were randomised to one of three groups that received two sequential depot injections of naltrexone (192 or 384 mg) or placebo injections. The mean dropout time was 48 days with high dose naltrexone compared with 27 days on placebo; an increase in <BR/>treatment of 21 days (range 11 to 31 days). The lower depot dose gave a lesser benefit. The number retained in treatment at eight weeks did not show a clear difference and ranged from a mean of 68% to 39% of participants in <BR/>the different groups. 'Wanting heroin' did not differ on naltrexone but 'needing heroin' scored significantly lower with depot naltrexone compared to placebo. The most prominent adverse effects were general symptoms of <BR/>fatigue and pain at the injection site. Seventeen reports met inclusion criteria for assessing adverse effects. Seven looked specifically at naltrexone implants for treatment of opioid dependence and wound infection, allergic reaction to the implant and number of implants removed. The majority of the trials did not have a control group and systematic assessment of adverse effects was lacking.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Naltrexone is an opioid antagonist which effectively blocks heroin effects. Since opioid dependence treatment with naltrexone tablets suffers from high dropout rates, several depot injections and implants are under investigation. Sustained-release formulations are claimed to be effective, but a systematic review of the literature is lacking.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness of sustained-release naltrexone for opioid dependence and its adverse effects in different study populations.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The following databases were searched from their inception to November 2007: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, LILACS, PsycINFO, ISI Web of Science, trial database at http://clinicaltrials.gov, available NIDA monographs, CPDD and AAAP conference proceedings. The reference lists of identified studies, published reviews and relevant web sides were searched manually. Study authors and drug companies were contacted to obtain any unpublished material or missing data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>To evaluate effectiveness only RCTs were included. To evaluate safety, any clinical trial reporting adverse effects was assessed. Treatment condition was extended to include alcohol dependent subjects and healthy volunteers. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Reviewers independently evaluated the reports, rated methodological quality and extracted data. Analyses were performed separately for opioid dependent, alcohol dependent and healthy participants.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Foe effectiveness, one report met inclusion criteria. Two dosages of naltrexone depot injections (192 and 384 mg) were compared to placebo. High-dose significantly increased days in treatment compared to placebo (WMD 21.00, 95% CI 10.68 to 31.32, p&lt;0.0001). High-dose compared to low-dose significantly increased days in treatment (WMD 12.00, 95% CI 1.69 to 22.31, p=0.02). Number of patients retained in treatment did not show significant differences between groups.</P>
<P>For adverse effects, seventeen reports met inclusion criteria analyses, six were RCTs. Side effects were significantly more frequent in naltrexone depot groups compared to placebo. In alcohol dependent samples only, adverse effects appeared to be significantly more frequent in the low-dose naltrexone depot groups compared to placebo (RR 1.18, 95% CI 1.02 to 1.36, p=0.02). In the opioid dependent sample, group differences were not statistically significant. Reports on systematic assessment of side effects and adverse events were scarce.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is insufficient evidence to evaluate the effectiveness of sustained-release naltrexone for treatment of opioid dependence.<BR/>For naltrexone injections, administration site-related adverse effects appear to be frequent, but of moderate intensity and time limited. For a harm-benefit evaluation of naltrexone implants, more data on side effects and adverse events are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-03-27 16:05:07 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-03-27 15:04:45 +0100" MODIFIED_BY="[Empty name]">
<P>Opioid dependence is considered a chronic lifelong relapsing disorder, which requires substantial therapeutic efforts to keep patients drug free (<LINK REF="REF-McLellan-2000" TYPE="REFERENCE">McLellan 2000</LINK>). The prevalence of opioid dependence is rather low and varies from 0.1 to 1.0 % among adult populations in Europe and the US, but reliable estimates are difficult to obtain (<LINK REF="REF-EMCDDA-2006" TYPE="REFERENCE">EMCDDA 2006</LINK>; <LINK REF="REF-OAS-2005" TYPE="REFERENCE">OAS 2005</LINK>).</P>
<P>The currently most effective and well-investigated treatment for opioid dependence is agonist replacement therapy with methadone (<LINK REF="REF-Amato-2005" TYPE="REFERENCE">Amato 2005</LINK>; <LINK REF="REF-Mattick-2003" TYPE="REFERENCE">Mattick 2003</LINK>; <LINK REF="REF-van-den-Brink-2006" TYPE="REFERENCE">van den Brink 2006</LINK>). Methadone Maintenance Treatment (MMT) implies supervised intake of a long-acting opioid receptor agonist. MMT reduces illicit opioid use and increases retention in treatment substantially. Despite evidence of its effectiveness, clinicians as well as users may be critical towards long-term prescription of a highly addictive drug. Hence, non-addictive alternatives have been in the focus of research for several decades.</P>
<P>Naltrexone is a long-acting, non-selective opioid-antagonist with highest affinity to mu-opioid receptors (<LINK REF="REF-Gonzalez-1988" TYPE="REFERENCE">Gonzalez 1988</LINK>). A daily ingested dose of 50 mg sufficiently blocks the effect of opioids to prevent relapse. Tolerance to and dependence on naltrexone does not develop (<LINK REF="REF-Navaratnam-1994" TYPE="REFERENCE">Navaratnam 1994</LINK>; <LINK REF="STD-Rawson-2000" TYPE="STUDY">Rawson 2000</LINK>). Oral naltrexone is approved for relapse prevention of alcohol and opioid dependence in several countries. Some trials showed promising results of oral naltrexone maintenance compared to placebo (<LINK REF="REF-Guo-2001" TYPE="REFERENCE">Guo 2001</LINK>), whereas others failed to detect an effect (<LINK REF="REF-San-1991" TYPE="REFERENCE">San 1991</LINK>). A Cochrane review did not find enough evidence to unequivocally support the clinical effectiveness of oral naltrexone in the treatment of opioid dependence (<LINK REF="REF-Minozzi-2006" TYPE="REFERENCE">Minozzi 2006</LINK>).</P>
<P>An important factor predicting treatment outcome of opioid dependence is treatment retention. Compared to agonist replacement therapy, the majority of opioid users are rather sceptical towards treatment with naltrexone tablets. Hence, maintenance therapy with oral naltrexone suffers from high early dropout rates, which has been counteracted by supervised ingestion of the tablets. Systematic use of incentives in order to externally strengthen patient motivation has been evaluated (<LINK REF="REF-Preston-1999" TYPE="REFERENCE">Preston 1999</LINK>). Another important variable to predict treatment outcome is vocational and social stability. Systematically selected and supposedly highly motivated patients seem to do better in oral naltrexone maintenance therapy than unbiased samples (<LINK REF="REF-Ginzburg-1984" TYPE="REFERENCE">Ginzburg 1984</LINK>; <LINK REF="REF-Cornish-1997" TYPE="REFERENCE">Cornish 1997</LINK>).</P>
<P>From a pharmacological point of view, efforts have been made to improve retention in treatment by administering naltrexone as a subcutaneous implant or depot injection. Development of sustained-release formulations commenced three decades ago (<LINK REF="REF-Chiang-1985" TYPE="REFERENCE">Chiang 1985</LINK>; <LINK REF="STD-Reuning-1976" TYPE="STUDY">Reuning 1976</LINK>). Only recently has sustained-release naltrexone become available for evaluation in larger human samples (<LINK REF="REF-Comer-2007" TYPE="REFERENCE">Comer 2007</LINK>). The objective of using sustained-release naltrexone is to secure medication compliance for weeks or even months, thus removing the onus from patients to take naltrexone tablets daily. At least 9 different sustained-release formulations are available. To date, none is approved for opioid dependence treatment in Australia, the EU or the US. Three depot injection formulations are under investigation, providing therapeutic naltrexone blood levels between 1 and 2 ng/ml for approximately 4 weeks: Vivitrol by Alkermes Inc., Depotrex by Biotek Inc. and Naltrel by Elbion. Another approach to provide therapeutic blood levels for several months is to load a biodegradable polylactic based polymer with naltrexone in implant formulations. Several implants are available commercially or through clinical trials: Sherman, Wedgewood, GoMedical (http://www.naltrexane.com/), Cravex (<LINK REF="REF-Partecke-2007" TYPE="REFERENCE">Partecke 2007</LINK>), Prodetoxone, which is approved for treatment of opioid dependence in Russia (<LINK REF="REF-Krupitsky-2007" TYPE="REFERENCE">Krupitsky 2007</LINK>) and a Chinese implant formulation (<LINK REF="REF-Moran-2007" TYPE="REFERENCE">Moran 2007</LINK>, see also http://www.1212.hk/). Since treatment with sustained-release naltrexone is hardly or even not reversible for a limited period of time, carefully assessing patients' motivation must be considered essential before treatment start. While results from clinical trials involving several hundred patients have been published, a systematic review of the literature is lacking.</P>
<P>The aim of this review is to evaluate the effectiveness and adverse effects of sustained-release naltrexone formulations used in humans.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effect of sustained-release naltrexone for opioid dependence compared to placebo or alternative treatment.<BR/>To evaluate adverse effects of sustained-release naltrexone formulations currently under investigation in different study populations.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>For assessment of effectiveness only randomised-controlled clinical trials on sustained-release naltrexone for treatment of opioid dependence were considered. For evaluation of safety and adverse effects prospective controlled and uncontrolled trials, case series and record-linkage studies were considered.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults or adolescents with opioid dependence. Studies investigating naltrexone treatment for other conditions were excluded for effectiveness evaluation.<BR/>For adverse effects evaluation only, any research on healthy participants and any research on treatment for other conditions than opioid dependence was included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any use of sustained-release formulations (i.e. depot or implant) of naltrexone compared to any other pharmacological or psychosocial or no treatment.<BR/>
</P>
<UL>
<LI>Sustained-release naltrexone versus oral naltrexone</LI>
<LI>Sustained-release naltrexone versus placebo</LI>
<LI>Sustained-release naltrexone versus agonist replacement therapy</LI>
<LI>Sustained-release naltrexone versus psychosocial interventions</LI>
<LI>Sustained-release naltrexone versus no treatment</LI>
</UL>
<P>Retrieved from literature search, but not predefined in protocol:<BR/>
</P>
<UL>
<LI>Low-dose versus high-dose sustained-release naltrexone</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Predefined primary outcomes:</B>
<BR/>(1) Opioid use during and after treatment: use/no use; number of days with use, self-report; number of positive urine samples per participant<BR/>(2) Treatment adherence:<BR/> a) Induction: started/not started<BR/> b) Compliance with protocol: days met for scheduled visits/not met; percentage met/not met; number of implants voluntarily removed.<BR/>(3) Retention in treatment: time to drop out.<BR/>(4) Adverse effects and severe AEs: percentage with/without; time to AE.</P>
<P>
<B>Predefined secondary outcomes:</B>(5) Use of illicit drugs other than opioids during and after treatment: use/no use; number of days with use, self-report; number of positive urine samples per patient(6) Criminal activity and incarceration: yes/no; number of days with criminal activity; number of offences; number of incarcerations; time spent in prison.<BR/>(7) Quality of life: as measured by validated and self-developed questionnaires, e.g. satisfaction with treatment on visual analogue scale (VAS).<BR/>(8) Mental health: any appropriate questionnaires; number of diagnoses.<BR/>(9) Duration of achieved therapeutic naltrexone blood levels: ng/ml as a function of time.</P>
<P>
<B>Outcome measures not considered in protocol but retrieved from literature search:</B>
<BR/>(10) Heroin craving</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-03-27 15:48:01 +0100" MODIFIED_BY="[Empty name]">
<P>To identify studies for this review detailed electronic searches for each data base were performed.</P>
<P>
<B>Electronic searches:<BR/>
</B>Electronic searches were performed to identify any RCTs investigating the effect of sustained-release naltrexone and any type of study on side effects and adverse events. The detailed search strategy was developed for MEDLINE but revised appropriately for each database to match vocabulary and syntax rules. No language restrictions were made.</P>
<P>The following databases were searched to identify reports on the effectiveness and adverse effects of sustained-release naltrexone:<BR/>1. Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2006) which includes the Cochrane Drugs and Alcohol Group Trials Register; 2. MEDLINE (January 1966 to November 2007); 3. EMBASE (1980 to 2007 week 45); 4. CINAHL - Cumulative Index to Nursing &amp; Allied Health Literature (1982 to November, week 2 2007); 5. LILACS (November 2007); 6. PsycINFO (1806 to November 2007); 7. ISI Web of Science (1975 to November 2007). Detailed search strategies for each databases are described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>
</P>
<P>
<B>Additional searches</B>
<BR/>Manual searches in reference lists, relevant web sites, the trial registers at http://www.clinicaltrials.gov and http://www.controlled-trials.com, conference abstracts (Annual Meetings of the College on Problems of Drug Dependence (CPDD), Annual Meetings of the American Academy of Addiction Psychiatry (AAAP)) were performed. Triallists and pharmaceutical companies were approached to obtain unpublished results, but contact proved difficult to establish.<B>
<BR/>
</B>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Study selection <BR/>
</B>Two authors independently assessed potentially relevant studies for inclusion. Any disagreement between the authors was resolved by discussion. If consensus was not achieved, the senior author was consulted. Missing information was sought by contacting study authors. <BR/>
<B>
<BR/>Assessment of methodological quality <BR/>
</B>Two authors independently assessed methodological quality of eligible studies. Any disagreement was resolved by consulting the senior author. Methodological quality assessment of all included studies was used to systematically describe possible bias and did not present a threshold for inclusion of trials.<BR/>Study quality of RCTs was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions criteria (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>):<BR/>
<B>
<BR/>
</B>
<B>
<I>(1) Measures to avoid selection bias</I>
</B>
<BR/>
<U>Allocation concealment in RCTs:</U>
<BR/>A) Adequate allocation concealment: central randomisation (e.g. allocation by a central office unaware of participant characteristics), pre-numbered or coded identical bottles or containers which are administered serially to participants, drug prepared by the pharmacy, serially numbered, opaque, sealed envelopes, on-site computer system combined with allocations kept in a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered, or other description that contained elements convincing of concealment.<BR/>B) Unclear allocation concealment: when the authors either did not report an allocation concealment approach at all or report an approach that did not fall in the category A or C.<BR/>C) Inadequate allocation concealment: alternation or reference to case numbers, dates of birth, day of the week. Any procedure that is entirely transparent before allocation, such as an open list of random numbers or other description that contained elements convincing of not concealment<BR/>D) no allocation concealment used</P>
<P>
<B>
<I>(2) Measures to avoid performance bias</I>
</B>
<I> </I>
<BR/>
<U>Blinding of those providing and receiving the intervention in RCTs:</U>
<BR/>A) double blind<BR/>B) single blind (blinding of participants)<BR/>C) unclear<BR/>D) no blinding</P>
<P>
<B>
<I>(3) Measures to avoid attrition bias</I>
</B>
<BR/>
<U>Description of drop outs in RCTs:</U>
<BR/>A) Loss to follow up completely recorded (for each group)<BR/>B) Loss to follow up incompletely recorded (data reported only for one group or for the overall sample)<BR/>C) Unclear or not done</P>
<P>
<B>
<I>(4) Measures to avoid detection bias</I>
</B>
<BR/>
<U>Blinding of the outcome assessor in RCTs:</U>
<BR/>A) Blind to treatment allocation at outcome assessment<BR/>B) Unclear<BR/>C) Not blind to treatment allocation at outcome assessment<BR/>
<B>
<BR/>Data collection<BR/>
</B>Two review authors independently extracted data using predefined data extraction forms. Any disagreement was resolved by consensus, if necessary by discussion with a third reviewer.<BR/>
<B>
<BR/>Data synthesis<BR/>
</B>Meta-analyses were performed were appropriate for all pre-specified outcomes. Individual and pooled relative risks (RR) with 95% confidence intervals (CI) were calculated for dichotomous outcomes, using the fixed-effects model unless studies were heterogeneous, in which case the random-effects model was used.<BR/>Statistical heterogeneity was assessed by the Chi-squared test, with P &lt; 0.05 indicating heterogeneity. Additionally, I-squared (values from 0 to 100 %, with 0 % indicating no observed heterogeneity) were calculated to assess inconsistency. Weighted mean differences (WMD) with 95% CI were calculated for continuous outcomes. From a clinical perspective, it seemed reasonable to analyse safety outcomes from reports on opioid dependent, alcohol dependent and healthy volunteers separately.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-03-27 15:49:23 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty eight reports of potential interest were identified and assessed, only 1 (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>) met criteria for inclusion into effectiveness analyses.<BR/>Seventeen of 68 identified reports were included to evaluate adverse effects of sustained-release naltrexone treatment (including <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>). In 2 reports the same population was investigated and only the primary publication (<LINK REF="STD-Waal-2003" TYPE="STUDY">Waal 2003</LINK>) was included. For adverse effects evaluation, unpublished data from 2 reports was retrieved and used (<LINK REF="STD-G_x00f6_lz-2000" TYPE="STUDY">Gölz 2000</LINK>, <LINK REF="STD-Waal-2003" TYPE="STUDY">Waal 2003</LINK>). A flow chart of the study inclusion process is provided in additional <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>
<B>Studies excluded from effectiveness and safety analyses</B>
<BR/>Reasons for exclusion of the remaining 50 reports were: publication was no clinical trial (25 reports), adverse effect data not provided (11 reports), intervention was oral naltrexone (9 reports), publication on pharmacokinetics of a non-recommendable formulation (3 reports), abstract available only (1 report), two references to same publication (1 report). <I>(See </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
<I>)<BR/>
</I>
<BR/>
<B>Included studies</B>
<BR/>
<B>
<U>(a) Study of effectiveness of sustained-release naltrexone for opioid dependence</U>
</B>
<BR/>One RCT ,conducted in the USA, met inclusion criteria (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>). A depot formulation of sustained-release naltrexone (Depotrex) was investigated among 60 outpatients. Three parallel groups received 2 sequential naltrexone injections of 192 mg or 384 mg, the control group received 2 placebo injections. In addition, all participants were offered manualised relapse prevention therapy. Clinic visits were scheduled twice weekly during the 8 weeks observation period. Primary outcome measures were treatment retention and opioid use assessed by urinalysis. Other illicit drug use, heroin craving, adverse effects, depression and severity of opioid and cocaine use were considered secondary outcomes. All outcome analyses were conducted on the intention-to-treat (ITT) population.</P>
<P>
<B>
<U>(b) Studies of adverse effects of sustained-release NTX</U>
</B>
<BR/>Seventeen reports were included in the adverse effect analyses, 6 were RCTs. <I>(See </I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>
<I>)<BR/>
</I>
<BR/>
</P>
<UL>
<LI>
<B>Populations</B>
</LI>
</UL>
<P>In 10 reports participants were opioid dependent. Two of these reports were restricted to a non-treatment seeking population (<LINK REF="STD-Comer-2002" TYPE="STUDY">Comer 2002</LINK>; <LINK REF="STD-Sullivan-2006" TYPE="STUDY">Sullivan 2006</LINK>). Sample sizes ranged from 5 (<LINK REF="STD-Sullivan-2006" TYPE="STUDY">Sullivan 2006</LINK>) to 894 participants (<LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK>) with a mean size of 168 participants (median=64.5). In 1 report (<LINK REF="STD-Dunbar-2006" TYPE="STUDY">Dunbar 2006</LINK>) the effects of sustained-release naltrexone on 42 healthy volunteers were investigated. Six reports on alcohol dependent subjects were included, with sample sizes ranging from 16 (<LINK REF="STD-Galloway-2005" TYPE="STUDY">Galloway 2005</LINK>) to 624 participants (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>) and a mean size of 174.7 participants (median=27.5).</P>
<UL>
<LI>
<B>Country</B>
</LI>
</UL>
<P>2 trials were conducted in Australia, 1 in Germany, 2 in Norway, 1 in Spain, 1 in the UK and 10 in the USA.</P>
<UL>
<LI>
<B>Interventions</B>
</LI>
</UL>
<P>The investigated drugs included 3 depot formulations (Alkermes, Biotek, DrugAbuse Sciences) containing 150 to 400 mg of naltrexone and 2 implant formulations (GoMedical, Wedgewood) containing 1000 to approximately 2200 mg of naltrexone. In 10 of 17 reports depot formulations of sustained-release naltrexone were used. The study samples were healthy volunteers, alcohol or opioid dependent patients in 1, 6 and 3 reports, respectively. In the remaining 7 reports on naltrexone implants, all participants were opioid dependent. <I>(See additional </I>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>
<I>)<BR/>
</I>
<BR/>
</P>
<UL>
<LI>
<B>Groups of comparison</B>
</LI>
</UL>
<P>
<U>Opioid dependent samples</U>
<BR/>Six of the 10 reports with opioid dependent samples were uncontrolled studies, 5 investigating naltrexone implants (<LINK REF="STD-Carreno-2003" TYPE="STUDY">Carreno 2003</LINK>; <LINK REF="STD-Foster-2003" TYPE="STUDY">Foster 2003</LINK>; <LINK REF="STD-Hulse-2005" TYPE="STUDY">Hulse 2005</LINK>; <LINK REF="STD-Waal-2003" TYPE="STUDY">Waal 2003</LINK>; <LINK REF="STD-Waal-2006" TYPE="STUDY">Waal 2006</LINK>) and 1 naltrexone depot (<LINK REF="STD-Sullivan-2006" TYPE="STUDY">Sullivan 2006</LINK>). Of the 4 reports with groups of comparison, the only RCT was conducted by <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>, comparing naltrexone depot to placebo injections. Two studies were designed with 2 sequential treatment groups, comparing low- and high-dose naltrexone depot (<LINK REF="STD-Comer-2002" TYPE="STUDY">Comer 2002</LINK>) or implants and oral naltrexone (<LINK REF="STD-G_x00f6_lz-2000" TYPE="STUDY">Gölz 2000</LINK>). One report compared naltrexone implants to methadone maintenance based on record-linkage data (<LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK>).</P>
<P>
<U>Alcohol dependent samples</U>
<BR/>In all 6 reports with alcohol dependent samples naltrexone depot injections were investigated. Four reports were RCTs (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>). In 1 report liver impaired patients were compared to matched, healthy controls (<LINK REF="STD-Turncliff-2005" TYPE="STUDY">Turncliff 2005</LINK>) and in 1 report a single treatment group was investigated (<LINK REF="STD-Galloway-2005" TYPE="STUDY">Galloway 2005</LINK>).</P>
<P>
<U>Healthy volunteers</U>
<BR/>In 1 dose-finding, phase I RCT naltrexone depot was investigated among healthy volunteers (<LINK REF="STD-Dunbar-2006" TYPE="STUDY">Dunbar 2006</LINK>).</P>
<P>
<B>Outcome measures</B>
<BR/>Two categories of adverse effects were assessed in 9 of the 17 reports: possibly naltrexone-related AEs (e.g. headache, nausea) and administration site-related AEs, such as itching, pain, tissue reactions or surgical site revision. In the majority of studies involving opioid dependent populations only administration site-related AEs were reported, however, in the record-linkage study by <LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK> mortality during course of treatment was investigated. Most reports on alcohol dependent subjects included assessment of AEs possibly related to both categories: the drug naltrexone and its particular formulation used. The predefined outcome measure<I> time to AE</I> was not assessed in any report.</P>
<P>
<B>Studies ongoing<BR/>
</B>We found six studies ongoing, as soon as results will be available, we will update the results.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<I>(See additional </I>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
<I>)</I>
</P>
<P>
<B>Study of effectiveness</B>
<BR/>In the 1 report included for analyses of effectiveness, the method of allocation concealment was not clearly described (category B). The trial was conducted in a double-blind fashion (category A) and loss to follow up was recorded completely for each treatment arm (category A). It remains unclear whether or not the outcome assessors were blind to which intervention participants had received (category B).</P>
<P>
<B>Studies of adverse effects<BR/>
</B>
<I>(see table characteristics of included studies)</I>
<B>
<BR/>
</B>
<U>RCTs: 6 reports</U>
<BR/>1) Comparison and allocation concealment:<BR/>In 1 of 6 RCTs an opioid dependent sample was investigated, this report was also included for analyses of effectiveness (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>). A detailed description of an adequate method for allocation concealment (category A) was provided by 1 study group (<LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>), the other 5 descriptions were rated category B: unclear allocation concealment. </P>
<P>2) Blinding of participant / provider:<BR/>All 6 RCTs were considered double-blind (category A), i.e. those receiving and providing treatment were blind to the intervention used.</P>
<P>3) Drop out:<BR/>In 5 RCTs loss to follow up was completely recorded for each treatment group (category A). The RCT by <LINK REF="STD-Dunbar-2006" TYPE="STUDY">Dunbar 2006</LINK> was rated category B: loss to follow up incompletely recorded.</P>
<P>4) Blinding of the outcome assessor:<BR/>One of 6 RCTs was considered triple blind: besides participants and treatment staff, researchers assessing outcomes were blind to treatment allocation (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>). The remaining 5 RCTs were rated category B: unclear if outcome assessor was blind to treatment allocation.</P>
<P>
<U>non-RCTs with parallel control group: 2 reports</U>
<BR/>
<LINK REF="STD-Turncliff-2005" TYPE="STUDY">Turncliff 2005</LINK> used a matched case-control design to compare liver impaired alcohol dependent patients and healthy controls. This trial was open-lable, loss to follow-up was completely recorded for each group. <LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK> retrospectively compared record-linkage data of opioid dependent patients receiving naltrexone implant to patients entering methadone maintenance. Patient data was recorded prospectively by health care staff who was considered blind to treatment condition. Reporting drop-out was not feasible due to record-linkage study design.<BR/>
<U>
<BR/>non-RCTs without parallel control group: 9 reports</U>
<BR/>Eight of the 9 reports were investigations on opioid dependent samples, only <LINK REF="STD-Galloway-2005" TYPE="STUDY">Galloway 2005</LINK> investigated an alcohol dependent sample. In 7 reports loss to follow up was completely recorded for treatment groups. In the remaining 2 reports the description of drop-outs was either not done (<LINK REF="STD-Carreno-2003" TYPE="STUDY">Carreno 2003</LINK>) or not feasible due to record-linkage study design (<LINK REF="STD-Hulse-2005" TYPE="STUDY">Hulse 2005</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-03-27 16:04:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<BR/>
</U>
</P>
<UL>
<LI>
<B>Effectiveness of sustained-release naltrexone for opioid dependence</B>
</LI>
</UL>
<P>For the 1 report (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>) that met inclusion criteria for effectiveness studies, the following primary treatment outcomes allowed calculations of effect estimates:<BR/>(1) Retention in treatment (number of participants in each group completing the 8-week study period)<BR/>(2) Time to drop out (number of days in treatment)</P>
<P>All confidence intervals are 95%, effect estimates are based on intention-to-treat analyses.</P>
<P>(1) <B>Retention in treatment</B> at week 8 was 68.2%, 60.0% and 38.9% of participants in the high dose, low dose and placebo group. There was no statistically significant difference between either dosage of depot naltrexone and placebo with high dose, one study, 40 participants, RR 1.75 (CI 0.92 to 3.34), <I>see </I>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; and low dose, one study, 38 participants, RR 1.54 (CI 0.78 to 3.05), <I>see </I>
<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. No statistically significant difference was found between groups receiving naltrexone depot, one study, 42 participants, RR 1.14 (CI 0.72 to 1.80), <I>see </I>
<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
<P>(2) <B>Time to drop out </B>was 48, 36 and 27 days in the high dose, low dose and placebo group. Group comparisons were statistically significant between high dose naltrexone depot and placebo, one study, 40 participants, WMD 21.0 (CI 10.68 to 31.32), <I>see</I> <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>, and between high and low dose depot, one study, 42 participants, WMD 12.0 (CI 1.69 to 22.31), <I>see </I>
<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>. There was no statistically significant difference between low dose depot and placebo, one study, 38 participants, WMD 9.0 (CI -3.40 to 21.40), <I>see </I>
<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.</P>
<P>The comparisons described below were regarded secondary outcomes by <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>. Calculation of effect estimates was not possible with the data provided.<BR/>(3) heroin craving assessed on visual analogue scales<BR/>(4) depression / severity of drug use<BR/>(5) naltrexone blood levels</P>
<P>(3) <B>Heroin craving,<I> </I>
</B>on visual analogue scales:<BR/>"Wanting heroin" did not show significant group differences throughout the study. "Needing heroin" was scored significantly lower by the high and low dose naltrexone depot group compared to the placebo group (p&lt;0.001).</P>
<P>(4) <B>Depression</B> (HAM-D scale); severity of opioid and cocaine use (CGIS):<BR/>No significant difference between treatment groups was reported on depression or severity of drug use scores. In regard to depression, all groups scored lower on HAM-D at follow-up than at baseline.</P>
<P>(5) <B>Mean plasma levels of naltrexone </B>during the 8 weeks study period ranged from 1.3 to 3.2 ng/ml in the high dose group. In the low dose group mean plasma levels were measured between 0.4 and 1.9 ng/ml. 4 weeks after the first injection plasma trough levels were reached and the naltrexone depot re-administered.</P>
<P>The following outcomes were predefined in the review's protocol, but not reported in <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>:<BR/>Opioid use per participant<BR/>Other drug use per participant<BR/>Treatment adherence<BR/>Criminal activity / incarceration</P>
<UL>
<LI>
<B>Adverse effects of sustained-release naltrexone treatment in RCTs</B>
</LI>
</UL>
<P>In 8 of the 17 reports included for assessment of adverse effects parallel comparison groups were used. Six of the 8 reports were RCTs (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>; <LINK REF="STD-Dunbar-2006" TYPE="STUDY">Dunbar 2006</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>) and 2 were non-RCTs (<LINK REF="STD-Turncliff-2005" TYPE="STUDY">Turncliff 2005</LINK>; <LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK>). In 7 of the 8 reports naltrexone depot injections were investigated and possibly drug-related adverse effects were assessed. Only Tait 2007 investigated naltrexone implants in comparison to methadone maintenance and assessed mortality. Effect analyses for non-RCTs were performed separately from the RCTs. Subgroup analyses were performed separately for the different populations, i.e. opioid dependent, alcohol dependent and healthy controls.</P>
<P>
<B>(1) RCTs</B>
<BR/>
<B>
<U>High-dose naltrexone depot compared to placebo injection:</U>
</B>
<U>
<BR/>
</U>
</P>
<UL>
<LI>
<B>Opioid dependence,</B> one RCT (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>):</LI>
</UL>
<P>No significant differences for reporting 1 or more adverse effects, 38 participants, RR 1.36 (CI 0.79 to 2.35), <I>see </I>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, sub-category 01 and for number of participants discontinuing the trial due to adverse effects, 38 participants, RR 0.28, (CI 0.01 to 6.38), <I>see </I>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, sub-category 02.</P>
<UL>
<LI>
<B>Alcohol dependence</B>, two RCTs (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK> and <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>):</LI>
</UL>
<P>Group differences of reporting 1 or more adverse effects were not significant in <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>, 30 participants, RR 1.15 (CI 0.73 to 1.81), <I>see</I> <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, sub-category 01. In <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>, no significant differences for reporting 1 or more severe adverse event , 414 participants, RR 0.68 (CI 0.31 to 1.48 ), <I>see </I>
<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, subcategory 02 and for reporting injection site pain ,414 participants, RR 1.29 (CI 0.73 to 2.28), <I>see</I> <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, sub-category 03., while de difference was statistically significant in favour of control group for number of participants discontinuing the trial due to adverse effects, 414 participants, RR 2.11 (CI 1.15 to 3.88), <I>see </I>
<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, sub-category 04.</P>
<P>
<B>
<U>Low-dose naltrexone depot compared to placebo injection:</U>
</B>
<U>
<BR/>
</U>
</P>
<UL>
<LI>
<B>Opioid dependence</B>, 1 RCT by <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>:</LI>
</UL>
<P>No significant differences between the groups for reporting 1 or more adverse effects, 38 participants, RR 1.30 (CI 0.74 to 2.28), <I>see</I> <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>, sub-category 01, number of participants discontinuing the trial due to adverse effects, 38 participants, RR 1.80 (CI 0.18 to 18.21), <I>see</I> <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>, sub-category 02 and reporting injection site induration RR 0.90 (CI 0.60 to 5.60), <I>see </I>
<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>, sub-category 03.<BR/>
<U>
<BR/>
</U>
</P>
<UL>
<LI>
<B>Alcohol dependence,</B> 3 RCTs by <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>
</LI>
</UL>
<P>In the trials by <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK> and <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK> group differences of reporting 1 or more adverse effects were not significant , 353 participants, RR 1.06 (CI 0.95 to 1.179, <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 01. In the trial by <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK> no differences for number of participants discontinuing the trial due to adverse effects, 419 participants, RR 1.00 (CI 0.49 to 2.04), <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 02. In all 3 trials group no statistically significant differences for reporting injection site pain, 772 participants, RR 1.17 (95% CI 0.92 to 1.47), <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 03. No statistically significant difference in <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK> and <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK> for reporting injection site induration , 353 participants, RR 1.17 (CI 0.76 to 1.80), <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 04. In <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK> no differences for reporting injection site contusion , 499 participants, RR 1.24, 95% (CI 0.60 to 2.57), <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 05, while the difference between groups was significantly in favour of control for reporting 1 or more injection site reaction, 333 participants, RR 1.19 (CI 1.02 to 1.38), <I>see</I> <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 06. In <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK> severe adverse events were described as most commonly hospital admissions for alcohol detoxification. Two cases of pneumonia were judged possibly naltrexone depot-related. Group differences of reporting an severe adverse events were not significant, 419 participants, RR 0.73 (CI 0.34 to 1.55), <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 07.<BR/>In all 3 trials group differences of reporting any type of injection site related adverse effect (i.e. injection site pain, induration, contusion and one or more reaction) was significant with pooled RR 1.18 (CI 1.02 to 1.36), <I>see </I>
<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, sub-category 08.</P>
<UL>
<LI>
<B>Healthy volunteers</B>, 1 RCT by <LINK REF="STD-Dunbar-2006" TYPE="STUDY">Dunbar 2006</LINK>:</LI>
</UL>
<P>No difference between the groups for reporting 1 or more AE were not significant , 42 participants, RR 2.46 (CI 0.16 to 38.89), <I>see </I>
<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>, sub-category 01 and for reporting one or more injection site reaction, 42 participants, RR 1.32 (CI 0.08 to 22.92), <I>see</I> <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>, sub-category 02.</P>
<P>
<B>
<U>High-dose compared to low-dose naltrexone depot: </U>
</B>
<U>
<BR/>
</U>
</P>
<UL>
<LI>
<B>Opioid dependence</B>, 1 RCT by <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>:</LI>
</UL>
<P>No difference for reporting 1 or more adverse effects , 42 participants, RR 1.05 (CI 0.68 to 1.6), <I>see </I>
<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>, sub-category 01) and for number of participants discontinuing the trial due to adverse effects, 42 participants, RR 0.18 (CI 0.01 to 3.59), <I>see </I>comparison <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>, sub-category 02.</P>
<UL>
<LI>
<B>Alcohol dependence</B>, 1 RCT by <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>:</LI>
</UL>
<P>Group differences for number of participants discontinuing the trial due to adverse effects were significant in favour of control, 415 participants, RR 2.12 (CI 1.02 to 3.22), <I>see </I>
<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>, sub-category 01. No significant differences for reporting injection site pain, 415 participants, RR 1.37 (CI 0.76 to 2.44), <I>see</I> <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>, sub-category 02 and for reporting an severe adverse effect (as described above), 415 participants, RR 0.93 (CI 0.40 to 2.15), <I>see </I>
<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>, sub-category 03.</P>
<P>
<B>(2) non-RCTs with parallel control group</B>
<BR/>
<U>Liver impaired compared to healthy controls:</U>
<BR/>In the report by <LINK REF="STD-Turncliff-2005" TYPE="STUDY">Turncliff 2005</LINK> the same dose of naltrexone depot (Alkermes Inc. 190 mg) was administered in two non-randomized groups: cases consisting of liver impaired, currently abstinent alcohol dependent patients matched to a control group of healthy volunteers. The relative risk of reporting 1 or more AE was statistically significant in favour of control, 25 participants, RR 3.25 (CI 1.14 to 9.24), <I>see</I> <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>.</P>
<P>
<U>Naltrexone implant compared to methadone maintenance:</U>
<BR/>In <LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK> mortality of two non-randomised cohorts of opioid dependent patients treated with naltrexone implants (GoMedical Inc.) or methadone maintenance is described. Of the 341 patients in the naltrexone group, 6 died in the study period between 2001 and 2006, whereas 15 of 553 patients in MMT died during those years. Group differences were not statistically significant with RR 0.65, CI 0.25 to 1.66 (<I>see </I>
<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>).</P>
<P>
<B>(3) Adverse effects of sustained-release naltrexone treatment reported in non-RCTs without control group</B>
</P>
<P>
<U>(a) Naltrexone implant (GoMedical Inc., Australia) for treatment of opioid dependence</U>
<BR/>In the report by <LINK REF="STD-Waal-2006" TYPE="STUDY">Waal 2006</LINK> a local tissue reaction was evident in 2 of 13 participants, in both cases the sites were surgically revised and the implants removed. According to unpublished data from this trial, possibly naltrexone-related adverse effects were decreasing during the course of the study, for example: irritability was reported by 6 of 12 patients 1 week after treatment start; at week 8 only 2 of 6 subjects reported irritability. Headache and nausea were experienced by 5, respectively 2 of 12 participants 1 week after treatment start. At week 8 none of the 6 patients still in treatment complained about headache or nausea.<BR/>In the report by <LINK REF="STD-Hulse-2005" TYPE="STUDY">Hulse 2005</LINK> 3 implant removals in 361 treated patients were registered: 1 due to wound infection and 2 on patients' request. No statement on possibly drug-related AEs or number of treatment responsive wound infections was made.</P>
<P>
<U>(b) Naltrexone implant (Wedgewood pharmacy, USA) for treatment of opioid dependence</U>
<BR/>Local tissue reactions occurred 7 times among 156 patients (<LINK REF="STD-Carreno-2003" TYPE="STUDY">Carreno 2003</LINK>). Furthermore 3 incidents of wound infection and no implant removal were reported in this sample. According to reports by <LINK REF="STD-Foster-2003" TYPE="STUDY">Foster 2003</LINK>; <LINK REF="STD-G_x00f6_lz-2000" TYPE="STUDY">Gölz 2000</LINK> and <LINK REF="STD-Waal-2003" TYPE="STUDY">Waal 2003</LINK> the numbers of local tissue reactions were 15 of 101, 25 of 104 and 2 of 10 patients, respectively. Unpublished data from <LINK REF="STD-G_x00f6_lz-2000" TYPE="STUDY">Gölz 2000</LINK> indicates wound infection in 6 of 104 patients (<LINK REF="REF-Partecke-2007" TYPE="REFERENCE">Partecke 2007</LINK>). In the first cohort of 55 patients from <LINK REF="STD-Foster-2003" TYPE="STUDY">Foster 2003</LINK>, 2 patients died during treatment. Both deaths were deemed unrelated to implant treatment. No death was reported during treatment in the second cohort of 46 patients. <LINK REF="STD-Waal-2003" TYPE="STUDY">Waal 2003</LINK> reports 3 implant removals, 2 due to adverse effects and 1 on patient's request. 6 of 10 patients complained about dysphoria during the course of the study.</P>
<P>
<U>(c) Naltrexone depot injection (Biotek Inc., USA) for treatment of opioid dependence</U>
<BR/>In the report by <LINK REF="STD-Comer-2002" TYPE="STUDY">Comer 2002</LINK>, 11 out of 12 participants experienced pain at the injection site, no incidence of induration, erythema or irritation was observed. According to <LINK REF="STD-Sullivan-2006" TYPE="STUDY">Sullivan 2006</LINK>, 3 out of 5 subjects complained about pain, a burning sensation or induration.</P>
<P>
<U>(d) Naltrexone depot injection (Elbion NV Belgium, formerly DrugAbuse Sciences Inc. USA) for treatment of alcohol dependence</U>
<BR/>All 16 participants in the report by <LINK REF="STD-Galloway-2005" TYPE="STUDY">Galloway 2005</LINK> experienced 1 or more possibly naltrexone-related adverse effect, 15 out of 16 reported administration site-related adverse effects. None of the adverse effects were rated serious (i.e. having significant medical consequences) by research staff.<U>
<BR/>
</U>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-03-27 16:05:07 +0100" MODIFIED_BY="[Empty name]">
<P>The main result of this review is a negative one: evidence to evaluate effectiveness of sustained-release naltrexone for treatment of opioid dependence is scarce. Only one report met inclusion criteria for analyses of effectiveness (<LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>). The naltrexone depot injection appeared dose-dependently beneficial: more subjects in the high-dose group spent longer time in treatment than subjects in the low-dose or placebo group. Time to drop-out was significantly longer in the high-dose group compared to the 2 other groups. Craving scores also seemed to support the effectiveness of sustained-release naltrexone, as scorings on "needing heroin", but not on "wanting heroin", were significantly lower in the groups receiving naltrexone depot. Urinalysis findings on heroin use were reported and indicated a considerable reduction in the high-dose group compared to the low-dose or placebo group. Since urinalysis findings could not be related to number of urine samples provided per participant, these data were omitted from our analyses and calculation of overall effect estimates was considered inappropriate. Despite consistent findings, we find it premature to conclude with the effectiveness of sustained-release naltrexone for treatment of opioid dependence on the basis of only one report. Any conclusion from a systematic literature review should be based on findings from several (at least two) clinical trials using satisfactory measures to limit possible bias.<BR/>One of the major challenges in oral naltrexone treatment has been high drop out rates, which are also reflected by the findings from the Cochrane review on oral naltrexone (<LINK REF="REF-Minozzi-2006" TYPE="REFERENCE">Minozzi 2006</LINK>). When comparing oral naltrexone with or without psychosocial support to placebo, two months retention rates did not exceed 60% (<LINK REF="STD-Lerner-1992" TYPE="STUDY">Lerner 1992</LINK>). The mean retention rate from the five included trials was as low as 33.3%. The two months retention rate of 68.2 % achieved in the high-dose depot group investigated by <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK>, indicates a considerable advantage of sustained-release naltrexone, which needs to be confirmed by further investigations.<BR/>For treatment of opioid dependence, only the Russian Federation has recently approved the naltrexone implant Prodetoxone (<LINK REF="REF-Krupitsky-2007" TYPE="REFERENCE">Krupitsky 2007</LINK>). However, our literature search did not retrieve any clinical trials on that formulation. Although to date evidence on effectiveness of sustained-release naltrexone for treatment of opioid dependence is clearly lacking, we would like to point out that several thousand opioid dependent patients are treated with naltrexone depots, and more frequently, implants. In Australia (<LINK REF="STD-Hulse-2005" TYPE="STUDY">Hulse 2005</LINK>; <LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK>) China (<LINK REF="REF-Moran-2007" TYPE="REFERENCE">Moran 2007</LINK>), Egypt (<LINK REF="REF-Maksoud-2006" TYPE="REFERENCE">Maksoud 2006</LINK>), Germany (<LINK REF="REF-Partecke-2007" TYPE="REFERENCE">Partecke 2007</LINK>), England (<LINK REF="STD-Brewer-2002" TYPE="STUDY">Brewer 2002</LINK>) and Russia (<LINK REF="STD-Ramenskaya-2005" TYPE="STUDY">Ramenskaya 2005</LINK>), naltrexone implants are used in clinical studies and, probably more widely, in private clinic settings. Independent of the circumstances of treatment, randomised-controlled trials seem to be the exception rather than the rule. Analysing reasons for the imbalance between number of opioid dependent patients in naltrexone implant treatment and number of good quality reports goes beyond the scope of this review.</P>
<P>The second objective of this systematic review was to assess the safety of sustained-release naltrexone when used in opioid and alcohol dependent samples and healthy volunteers. Safety outcomes were assessed separately for the three different populations. From a clinical perspective, qualitatively similar adverse effects would be expected regardless of treatment condition, but frequency of reporting may differ considerably due to different treatment goals in opioid (blocking the effect) and alcohol (reducing craving) dependence. Therefore, performing meta-analyses was regarded inappropriate. Nevertheless, alcohol dependent samples may contribute substantially to safety evaluation by illustrating trends applicable to opioid dependent samples.<BR/>
<U>
<BR/>Possibly naltrexone-related adverse effects</U>
<BR/>Findings on supposedly naltrexone-related adverse effects revealed significant group differences for nausea, fatigue, vomiting, decreased appetite, dizziness and upper abdominal pain in alcohol dependent patients (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>, data not shown). These adverse effects seemed to occur in a dose-related fashion and most infrequently in the placebo group. Findings are consistent with side effects of oral naltrexone treatment described earlier (<LINK REF="REF-Martin-1973" TYPE="REFERENCE">Martin 1973</LINK>).<BR/>For an opioid dependent sample, <LINK REF="STD-Comer-2006" TYPE="STUDY">Comer 2006</LINK> reports adverse effects with the most prominent symptoms being general disorders such as fatigue and administration site-related conditions. The composite outcome one or more adverse effect did not reach statistical significance, but was less frequently reported in the placebo group. These findings are in line with the Cochrane review on oral naltrexone (<LINK REF="REF-Minozzi-2006" TYPE="REFERENCE">Minozzi 2006</LINK>).<BR/>Although the number of possibly naltrexone-related adverse effects was not significantly different between groups in any RCT, the placebo groups reported adverse effects less frequently, independent of the condition studied. Severe adverse events, as reported by <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>, were mostly hospital admissions for alcohol detoxification and favoured the naltrexone depot group. Six of ten opioid dependent participants in <LINK REF="STD-Waal-2003" TYPE="STUDY">Waal 2003</LINK> complained about dysphoria, but this trial lacks a control group. In another trial without a control group (<LINK REF="STD-Waal-2006" TYPE="STUDY">Waal 2006</LINK>), complaints about adverse effects possibly caused by naltrexone (e.g. irritability, headache, nausea) were decreasing during the course of the study.</P>
<P>
<U>Administration site-related adverse effects and mortality</U>
<BR/>Findings for administration site-related adverse effects showed no significant group differences for injection site pain, -induration, or -contusion. In the report by <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK> the naltrexone depot group reported more frequently than the placebo group one or more injection site reaction. Moreover, the composite outcome any injection site-related adverse effect showed a statistically significant advantage of the placebo group compared to low-dose naltrexone in alcohol dependent samples (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>).<BR/>In the seven reports on naltrexone implant for treatment of opioid dependence, adverse effect assessment consisted of wound infection, allergic reaction to foreign body and number of implants removed. However, findings should be interpreted with caution, as the majority of the trials did not have a control group. Besides, systematic assessment of adverse effects was mostly lacking and loss to follow-up was not always reported completely. We therefore find it inappropriate to calculate prevalence of allergic reactions or wound infections. Nevertheless, it should be kept in mind that these adverse effects do occur with any of the implant formulations investigated and that they may lead to surgical revision of the implant site.<BR/>The non-randomised trial which investigated mortality had several limitations and causality to interpret group differences cannot be imputed (<LINK REF="STD-Tait-2007" TYPE="STUDY">Tait 2007</LINK>). Data is based on retrospective record-linkage and information on number and duration of treatment episodes was unavailable for both groups.</P>
<P>When gathering data on adverse effects, substantial differences in methodological quality became obvious (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Four of the six reports on alcohol dependent patients were double-blind, placebo-controlled, randomised trials providing complete information on participants lost to follow-up. Only one out of ten reports on opioid dependent patients met a similar standard. Systematic assessment of drug- and administration site-related adverse effects was more prevalent in research involving alcohol dependent subjects compared to opioid dependent subjects. Regardless of the condition studied, any trial on experimental treatment such as sustained-release naltrexone, should be subject to the same quality requirements, i.e. active assessment and log of adverse effects, events and severe adverse events.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>To date, there is insufficient evidence to evaluate effectiveness of sustained-release naltrexone for treatment of opioid dependence. Sustained-release naltrexone formulations should still be considered investigational drugs, however, naltrexone depot injections available today seem promising in the treatment of opioid dependence.<BR/>Findings of possibly sustained-release naltrexone-related side effects are in line with research on naltrexone tablets. For naltrexone depot injections, administration site-related adverse effects such as pain appear to be frequent, but usually of moderate intensity and time limited. Data on administration site-related adverse effects of naltrexone implants is scarce. Hence, commercial use of any implant formulation still needs to be evaluated thoroughly.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future studies of sustained-release naltrexone involving opioid dependent patients should provide a complete description of drop-out and be conducted with a control group, preferably in a randomised-controlled fashion. RCTs evaluating effectiveness for treatment of opioid dependence should compare sustained-release naltrexone to oral naltrexone or agonist replacement treatment with methadone or buprenorphine. Besides effectiveness, any research on naltrexone implants should also focus on safety to make an analysis of harm-benefit possible.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Karianne Hammerstrøm, Anne Ekanger and Ingvild Kirkehei from the Norwegian Knowledge Centre for the Health Services and Simona Vecchi from the Department of Epidemiology ASL RME, Rome, Italy for conducting literature searches for this review. We are also grateful to Dres. Hulse, Krupitsky, Partecke, Waal and Woody for supporting our work by providing unpublished data and additional information. Finally, we would like to thank our contact editor from the Cochrane Drugs and Alcohol Group Dr Silvia Minozzi.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Three review authors (PL, HK, NK) independently assessed potentially relevant studies for inclusion. If consensus was not achieved, the senior reviewer (AB) was consulted. Two review authors (PL, HK) independently extracted data and independently assessed methodological quality of eligible studies. A third review author resolved any disagreements. All four review authors read, discussed and approved this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-03-27 16:13:46 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-03-27 16:12:34 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-03-27 16:11:44 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carreno-2003" NAME="Carreno 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>LinksCarreño JE, Alvarez CE, Narciso GI, Bascarán MT, Díaz M, Bobes J</AU>
<TI>Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence</TI>
<SO>Addict Biol</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>4</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comer-2002" NAME="Comer 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW</AU>
<TI>Depot naltrexone: long-lasting antagonism of the effects of heroin in humans</TI>
<SO>Psychopharmacology</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>4</NO>
<PG>351-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comer-2006" MODIFIED="2008-03-27 16:11:36 +0100" MODIFIED_BY="[Empty name]" NAME="Comer 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-03-27 16:11:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al</AU>
<TI>Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomised, placebo-controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>2</NO>
<PG>210-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunbar-2006" NAME="Dunbar 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC</AU>
<TI>Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone</TI>
<SO>Alcoholism: Clinical &amp; Experimental Research</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>3</NO>
<PG>480-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-2003" MODIFIED="2008-03-27 16:11:44 +0100" MODIFIED_BY="[Empty name]" NAME="Foster 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-03-27 16:11:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Foster J, Brewer C, Steele T</AU>
<TI>Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totaling 101 patients with a note on naltrexone blood levels</TI>
<SO>Addiction Biology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galloway-2005" NAME="Galloway 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Galloway GP, Koch M, Cello R, Smith DE</AU>
<TI>Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial</TI>
<SO>BMC Psychiatry</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garbutt-2005" NAME="Garbutt 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al</AU>
<TI>Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>13</NO>
<PG>1617-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR</AU>
<TI>Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-G_x00f6_lz-2000" NAME="Gölz 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gölz J, Partecke G</AU>
<TI>Catamnestic development of opiate addicts after Naltrexone induced detoxification under anaesthesia, Naltrexone supported relapse prevention and psychosocial outpatient aftercare</TI>
<TO>Katamnestische Entwicklung Opiatabhängiger nach Naltrexoninduziertem Entzug unter Narkose, naltrexongestützter Rückfallprophylaxe und ambulanter psychosozialer Nachsorge</TO>
<SO>Suchttherapie</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>3</NO>
<PG>166-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Hulse-2005" NAME="Hulse 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D</AU>
<TI>Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>3</NO>
<PG>351-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" NAME="Johnson 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Ait-Daoud N, Aubin HJ, Van Den BW, Guzzetta R, Loewy J, et al</AU>
<TI>A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence</TI>
<SO>Alcoholism: Clinical &amp; Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1356-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-1998" NAME="Kranzler 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Modesto-Lowe V, Nuwayser ES</AU>
<TI>Sustained-release naltrexone for alcoholism treatment: a preliminary study</TI>
<SO>Alcoholism: Clinical &amp; Experimental Research</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>5</NO>
<PG>1074-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-2004" NAME="Kranzler 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Wesson DR, Billot L, DrugAbuse Sciences Naltrexone Depot Study Group</AU>
<TI>Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo-Controlled Clinical Trial</TI>
<SO>Alcoholism: Clinical &amp; Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>7</NO>
<PG>1051-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-2006" NAME="Sullivan 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan MA, Vosburg SK, Comer SD</AU>
<TI>Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>189</VL>
<NO>1</NO>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tait-2007" NAME="Tait 2007" YEAR="2007">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Tait RJ, Ngo HT, Hulse GK</AU>
<TI>Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment</TI>
<SO>Journal of Substance Abuse Treatment in press</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turncliff-2005" NAME="Turncliff 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, et al</AU>
<TI>Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>11</NO>
<PG>1259-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Waal-2003" NAME="Waal 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen L, Christophersen AS, Frogopsahl G, Waal H, Morland J</AU>
<TI>Plasma concentrations during naltrexone implant treatment of opiate-dependent patients</TI>
<SO>British journal of clinical pharmacology</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>2</NO>
<PG>219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waal H, Christophersen AS, Frogopsahl G, Olsen LH, Morland J</AU>
<TI>[Naltrexone implants--a pilot project]</TI>
<SO>The Journal of the Norwegian Medical Association</SO>
<YR>2003</YR>
<VL>123</VL>
<NO>12</NO>
<PG>1660-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waal-2006" NAME="Waal 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waal H, Frogopsahl G, Olsen L, Christophersen AS, Morland J</AU>
<TI>Naltrexone implants - duration, tolerability and clinical usefulness. A pilot study</TI>
<SO>European Addiction Research</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>3</NO>
<PG>138-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-03-27 16:12:34 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Albanese-2000" NAME="Albanese 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albanese AP, Gevirtz C, Oppenheim B, Field JM, Abels I, Eustace JC</AU>
<TI>Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD)</TI>
<SO>Journa of Addictive Diseases</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>11-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brewer-2001" NAME="Brewer 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brewer C</AU>
<TI>Naltrexone implants for opiate addiction: New life for a middle-aged drug</TI>
<SO>Pharmaceutical Journal</SO>
<YR>2001</YR>
<VL>267</VL>
<NO>7162</NO>
<PG>260</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brewer-2002" NAME="Brewer 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brewer C</AU>
<TI>Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases</TI>
<SO>Addiction Biology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>3</NO>
<PG>321-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brewer-2004" NAME="Brewer 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brewer C, Wong VS</AU>
<TI>Naltrexone: Report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature</TI>
<SO>Addiction Biology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carreno-2002" NAME="Carreno 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carreno JE, Bobes J, Brewer C, Alvarez CE, San Narciso GI, Bascaran MT, et al</AU>
<TI>24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures</TI>
<SO>Addiction Biology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>2</NO>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiang-1984" NAME="Chiang 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiang CN, Hollister LE, Kishimoto A, Barnett G</AU>
<TI>Kinetics of a naltrexone sustained-release preparation</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>5</NO>
<PG>704-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiang-1985a" NAME="Chiang 1985a" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiang CN, Hollister LE, Gillespie HK, Foltz RL</AU>
<TI>Clinical evaluation of a naltrexone sustained-release preparation</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1985</YR>
<VL>16</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiang-1985b" NAME="Chiang 1985b" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiang CN, Kishimoto A, Barnett G, Hollister LE</AU>
<TI>Implantable narcotic antagonists: a possible new treatment for narcotic addiction</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>3</NO>
<PG>672-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2005" MODIFIED="2008-03-27 16:12:00 +0100" MODIFIED_BY="[Empty name]" NAME="Collins 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-03-27 16:12:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins ED, Kleber HD, Whittington RA, Heitler NE</AU>
<TI>Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomised trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>8</NO>
<PG>903-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colquhoun-2005" NAME="Colquhoun 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colquhoun R, Tan DY, Hull S</AU>
<TI>A comparison of oral and implant naltrexone outcomes at 12 months</TI>
<SO>Journal of Opioid Management</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>5</NO>
<PG>249-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dean-2005" NAME="Dean 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dean RL</AU>
<TI>The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence</TI>
<SO>Frontiers in Bioscience</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>643-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dean-2006" MODIFIED="2008-03-27 16:12:09 +0100" MODIFIED_BY="[Empty name]" NAME="Dean 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-03-27 16:12:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR</AU>
<TI>Does naltrexone treatment lead to depression? Findings from a randomised controlled trial in subjects with opioid dependence</TI>
<SO>Journal of Psychiatry and Neuroscience</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>1</NO>
<PG>38-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Alonso-1989" MODIFIED="2008-03-27 16:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Alonso 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-03-27 16:12:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Alonso F, Gutierrez M, San L, Bedate J, Forteza-Rei J, Rodriguez-Artalejo F, et al</AU>
<TI>A multi centre study to introduce naltrexone for opiate dependence in Spain</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1989</YR>
<VL>23</VL>
<NO>2</NO>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gooberman-1998" MODIFIED="2008-03-27 16:12:34 +0100" MODIFIED_BY="[Empty name]" NAME="Gooberman 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-03-27 16:12:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gooberman LL, Bradway DW</AU>
<TI>Depot naltrexone vs oral naltrexone post detoxification</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>2</NO>
<PG>150</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grusser-2006" NAME="Grusser 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grusser SM, Thalemann CN, Platz W, Golz J, Partecke G</AU>
<TI>A new approach to preventing relapse in opiate addicts: A psychometric evaluation</TI>
<SO>Biological Psychology</SO>
<YR>2006</YR>
<VL>71</VL>
<NO>3</NO>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamilton-2002" NAME="Hamilton 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton RJ, Olmedo RE, Shah S, Hung OL, Howland MA, Perrone J, et al</AU>
<TI>Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets</TI>
<SO>Academic emergency medicine</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>1</NO>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2006" NAME="Harrison 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison TS, Plosker GL, Keam SJ</AU>
<TI>Extended-release intramuscular naltrexone</TI>
<SO>Drugs</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>1741-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heading-2006" NAME="Heading 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heading CE</AU>
<TI>Vivitrex (Alkermes/Cephalon)</TI>
<SO>Current Opinion in Investigational Drugs</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>1</NO>
<PG>81-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2002a" NAME="Hulse 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse G, O'neil G</AU>
<TI>Using naltrexone implants in the management of the pregnant heroin user</TI>
<SO>Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology</SO>
<YR>2002</YR>
<VL>42</VL>
<NO>5</NO>
<PG>569-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2002b" NAME="Hulse 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, O'Neill G</AU>
<TI>A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user</TI>
<SO>Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology</SO>
<YR>2002</YR>
<VL>42</VL>
<NO>1</NO>
<PG>93-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2003a" NAME="Hulse 2003a" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, Tait RJ</AU>
<TI>A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users</TI>
<SO>Addiction Biology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>3</NO>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2003b" NAME="Hulse 2003b" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, O'neil G, Hatton M, Paech MJ</AU>
<TI>Use of oral and implantable naltrexone in the management of the opioid impaired physician.[see comment]</TI>
<SO>Anaesthesia &amp; Intensive Care</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>2</NO>
<PG>196-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2003c" NAME="Hulse 2003c" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, Arnold-Reed DE, O'Neil G, Hansson RC</AU>
<TI>Naltrexone implant and blood naltrexone levels over pregnancy</TI>
<SO>Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology</SO>
<YR>2003</YR>
<VL>43</VL>
<NO>5</NO>
<PG>386-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2004a" NAME="Hulse 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P</AU>
<TI>Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants</TI>
<SO>Addiction Biology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2004b" NAME="Hulse 2004b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC</AU>
<TI>Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants</TI>
<SO>Addiction Biology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2004c" NAME="Hulse 2004c" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, O'neil G, Arnold-Reed DE</AU>
<TI>Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user</TI>
<SO>International Journal of Gynaecology &amp; Obstetrics</SO>
<YR>2004</YR>
<VL>85</VL>
<NO>2</NO>
<PG>170-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse-2004d" NAME="Hulse 2004d" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulse GK, O'neil G, Arnold-Reed DE</AU>
<TI>Management of an opioid-impaired anaesthetist by implantable naltrexone</TI>
<SO>Journal of Substance Use</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>2</NO>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iversen-2005" NAME="Iversen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iversen L</AU>
<TI>Addiction</TI>
<SO>Drug Discovery Today: Therapeutic Strategies</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>v</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Jasinski-2006" NAME="Jasinski 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Jasinski DR</AU>
<TI>Clinical Studies of a Long-Acting Naltrexone Implant for Opioid Addiction</TI>
<SO>http://www.valerapharma.com/</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeffrey-2007" NAME="Jeffrey 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, et al</AU>
<TI>Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.[see comment]</TI>
<SO>Hepatology</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>1</NO>
<PG>111-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2006" NAME="Johnson 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA</AU>
<TI>A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1065-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lerner-1992" NAME="Lerner 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerner A, Sigal M, Bacalu A, Shiff R, Burganski I, Gelkopf M</AU>
<TI>A naltrexone double blind placebo controlled study in Israel</TI>
<SO>The Israel journal of psychiatry and related sciences</SO>
<YR>1992</YR>
<VL>29</VL>
<NO>1</NO>
<PG>36-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marlowe-2006" NAME="Marlowe 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marlowe DB</AU>
<TI>Depot naltrexone in lieu of incarceration: A behavioral analysis of coerced treatment for addicted offenders</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2</NO>
<PG>131-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1974" NAME="Martin 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin WR, Sandquist VL</AU>
<TI>A sustained release depot for narcotic antagonists</TI>
<SO>Arch Gen Psychiatry</SO>
<YR>1974</YR>
<VL>30</VL>
<NO>1</NO>
<PG>31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modesto_x002d_Lowe-2002" NAME="Modesto-Lowe 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modesto-Lowe V</AU>
<TI>Naltrexone depot Drug Abuse Sciences</TI>
<SO>IDrugs</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>8</NO>
<PG>835-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ngo-2007" NAME="Ngo 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ngo HT, Tait RJ, Arnold-Reed DE, Hulse GK</AU>
<TI>Mental health outcomes following naltrexone implant treatment for heroin-dependence</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>3</NO>
<PG>605-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NRCC-report-1978" NAME="NRCC report 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>NRCC report 1978</AU>
<TI>Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<NO>3</NO>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2005" NAME="O'Brien 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien CP</AU>
<TI>Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence</TI>
<SO>Current Psychiatry Reports</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>5</NO>
<PG>327-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2006" NAME="O'Brien 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien B, Cody C</AU>
<TI>Analgesia and sedation in the presence of a naltrexone implant: A novel pharmacological challenge</TI>
<SO>European Journal of Emergency Medicine</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>5</NO>
<PG>315-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Malley-1992" NAME="O'Malley 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B</AU>
<TI>Naltrexone and coping skills therapy for alcohol dependence. A controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>11</NO>
<PG>881-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliver-2005" NAME="Oliver 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliver P, Horspool M, Keen J</AU>
<TI>Fatal opiate overdose following regimen changes in naltrexone treatment [1]</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>4</NO>
<PG>560-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pekta-1998" NAME="Pekta 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pekta SNO, Kalyonko ÖA, Mirsal H, Pektas A, Gooberman LL, Beyazyürek M</AU>
<TI>Different forms (Oral or implant) Of naltrexone use in relapse prevention on heroin addicts: A controlled clinical trial up to 6 months follow-up</TI>
<SO>XXIst Collegium Internationale Neuro psychopharmacologicum, Glasgow, Scotland 12th 16th July, 1998</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitt-1981" NAME="Pitt 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitt CG, Marks TA, Schindler A</AU>
<TI>Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists</TI>
<SO>NIDA Research Monograph</SO>
<YR>1981</YR>
<VL>28</VL>
<PG>232-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poser-1996" NAME="Poser 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poser W, Ehrenreich H</AU>
<TI>Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism</TI>
<SO>Internist</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>10</NO>
<PG>1061-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabinowitz-1998" NAME="Rabinowitz 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabinowitz J, Cohen H, Kotler M</AU>
<TI>Outcomes of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling</TI>
<SO>American Journal on Addictions</SO>
<YR>1998</YR>
<VL>49</VL>
<NO>6</NO>
<PG>831-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramenskaya-2005" NAME="Ramenskaya 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramenskaya GV, Shikh EV, Arzamastsev AP, Kukes VG</AU>
<TI>Molecular-biological problems of drug design and mechanism of drug action - Pharmacokinetic study of the new domestic hypodermic form of naltrexone: Prodetoxon depot tablets</TI>
<SO>Pharmaceutical Chemistry Journal</SO>
<YR>2005</YR>
<VL>1</VL>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rawson-2000" NAME="Rawson 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rawson RA, McCann MJ, Hasson AJ, Ling W</AU>
<TI>Addiction pharmacotherapy 2000: new options, new challenges</TI>
<SO>Journal of Psychoactive Drugs</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>4</NO>
<PG>371-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reece-2007" NAME="Reece 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reece AS</AU>
<TI>Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program</TI>
<SO>Subst Abuse Treat Prev Policy</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>1</NO>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Resnick-1977" NAME="Resnick 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnick RB</AU>
<TI>Prospects, problems, side effects, and safety of narcotic antagonists</TI>
<SO>International Journal of the Addictions</SO>
<YR>1977</YR>
<VL>12</VL>
<NO>7</NO>
<PG>863-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuning-1976" NAME="Reuning 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuning RH, Malspeis L, Frank S, Notari RE</AU>
<TI>Testing of drug delivery systems for use in the treatment of narcotic addiction</TI>
<SO>NIDA</SO>
<YR>1976</YR>
<VL>4</VL>
<PG>43-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-2001" NAME="Riddle 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MA, Kastelic EA, Frosch E</AU>
<TI>Pediatric psychopharmacology</TI>
<SO>Journal of Child Psychology &amp; Psychiatry &amp; Allied Disciplines</SO>
<YR>2001</YR>
<VL>42</VL>
<NO>1</NO>
<PG>73-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwope-1975" NAME="Schwope 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwope AD, Wise DL, Howes JF</AU>
<TI>Lactic/glycolic acid polymers as narcotic antagonist delivery systems</TI>
<SO>Life Sciences</SO>
<YR>1975</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1877-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobel-2001" NAME="Sobel 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobel BFX, Liesbon IA, Bigelow GE</AU>
<TI>Prolonged opioid blockade by depot naltrexone</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2001</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suhaida-2004" NAME="Suhaida 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suhaida MG, Yahya IB, Darmawati MY</AU>
<TI>Preparation of naltrexone hydrochloride loaded poly (DL-lactide-co-glycolide) microspheres and the effect of polyvinyl alcohol (PVA) as surfactant on the characteristics of the microspheres</TI>
<SO>Medical Journal of Malaysia</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>Supplement B</NO>
<PG>63-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teagle-2007" NAME="Teagle 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teagle S</AU>
<TI>Depot naltrexone appears safe and effective for heroin addiction</TI>
<SO>Nida Notes</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>3</NO>
<PG>7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warhaft-2003" NAME="Warhaft 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warhaft N</AU>
<TI>Naltrexone implants</TI>
<SO>Anaesthesia &amp; Intensive Care</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>5</NO>
<PG>592-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wesson-2003" NAME="Wesson 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wesson DR, Kranzler HR, Kusmierek J</AU>
<TI>A placebo-controlled, clinical trial of naltrexone depot in treatment of alcohol dependence: Results at 9 and 12 months</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>2</NO>
<PG>121</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willette-1978" NAME="Willette 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willette RE</AU>
<TI>The development of sustained action preparations of narcotic antagonists</TI>
<SO>NIDA Research Monograph</SO>
<YR>1978</YR>
<VL>19</VL>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Willette-1981" NAME="Willette 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Willette RE, Barnett G editors</AU>
<TI>Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations</TI>
<SO>NIDA Research Monograph</SO>
<YR>1981</YR>
<VL>28</VL>
<PG>1-273</PG>
<PB>U.S. Government</PB>
<CY>Washington, D.C</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wodak-2001" NAME="Wodak 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wodak A</AU>
<TI>Drug treatment for opioid dependence</TI>
<SO>Australian Prescriber</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>4-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulse" NAME="Hulse" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Hulse GK, Arnold-Reed D, Bulsara M</AU>
<TI>A randomised, double-blind, placebo-controlled clinical trial of naltrexone implants for the treatment of heroin addiction</TI>
<SO>personal communication</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kun_x00f8_e" NAME="Kunøe" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kunøe</AU>
<TI>Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study</TI>
<SO>http://clinicaltrials.gov identifier: NCT00521157</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobmaier" NAME="Lobmaier" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lobmaier P</AU>
<TI>Naltrexone Implants - a Treatment Alternative for Heroin Dependent Prisoners?</TI>
<SO>http://clinicaltrials.gov identifier: NCT00204243</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nunes-2002" NAME="Nunes 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Nunes E</AU>
<TI>Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence</TI>
<SO>http://clinicaltrials.gov identifier NCT00332228</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nunes-2008" NAME="Nunes 2008" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Nunes E</AU>
<TI>Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-Oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial</TI>
<SO>Clinicaltrial.gov reference: NCT00577408</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiihonen" NAME="Tiihonen" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Tiihonen J</AU>
<TI>Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence: a double-blind, randomised, placebo-controlled trial</TI>
<SO>http://www.controlled-trials.com/</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN88905555"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woody" NAME="Woody" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Woody G</AU>
<TI>Addiction Treatment in Russia: Oral and Depot Naltrexone</TI>
<SO>http://clinicaltrials.gov identifier NCT00218426</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-03-27 16:13:46 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-03-27 16:13:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amato-2005" NAME="Amato 2005" TYPE="JOURNAL_ARTICLE">
<AU>Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P</AU>
<TI>An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>4</NO>
<PG>321-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chiang-1985" NAME="Chiang 1985" TYPE="JOURNAL_ARTICLE">
<AU>Chiang CN, Hollister LE, Gillespie HK, Foltz RL</AU>
<TI>Clinical evaluation of a naltrexone sustained-release preparation</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1985</YR>
<VL>16</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Comer-2007" NAME="Comer 2007" TYPE="JOURNAL_ARTICLE">
<AU>Comer SD, Sullivan MA, Hulse GK</AU>
<TI>Sustained-release naltrexone: novel treatment for opioid dependence</TI>
<SO>Expert Opin Investig Drugs</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>8</NO>
<PG>1285-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornish-1997" NAME="Cornish 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, et al</AU>
<TI>Naltrexone pharmacotherapy for opioid dependent federal probationers</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>6</NO>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMCDDA-2006" NAME="EMCDDA 2006" TYPE="OTHER">
<AU>EMCDDA</AU>
<TI>11th annual report 2006</TI>
<SO>http://ar2006.emcdda.europa.eu/download/ar2006-en.pdf</SO>
<YR>(accessed 31 August 2007)</YR>
<PB>EMCDDA</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ginzburg-1984" NAME="Ginzburg 1984" TYPE="JOURNAL_ARTICLE">
<AU>Ginzburg HM, Glass WJ</AU>
<TI>The role of the National Institute on Drug Abuse in the development of naltrexone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>9</NO>
<PG>4-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-1988" NAME="Gonzalez 1988" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez JP, Brogden RN</AU>
<TI>Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence</TI>
<SO>Drugs</SO>
<YR>1988</YR>
<VL>35</VL>
<NO>3</NO>
<PG>192-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guo-2001" NAME="Guo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Guo S, Jiang Z, Wu Y</AU>
<TI>Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification</TI>
<SO>Hong Kong Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>4</NO>
<PG>2-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors.</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005].</TI>
<SO>The Cochrane Library, Issue 2.</SO>
<YR>2006</YR>
<PB>John Wiley &amp; Sons, Ltd. Cochrane Collaboration, 2006.</PB>
<CY>Chichester, UK:</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krupitsky-2007" NAME="Krupitsky 2007" TYPE="JOURNAL_ARTICLE">
<AU>Krupitsky EM, Burakov AM, Tsoy MV, Egorova VY, Slavina TY, Grinenko AY, et al</AU>
<TI>Overcoming opioid blockade from depot naltrexone (Prodetoxon)</TI>
<SO>Addiction</SO>
<YR>2007</YR>
<VL>102</VL>
<NO>7</NO>
<PG>1164-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maksoud-2006" NAME="Maksoud 2006" TYPE="CONFERENCE_PROC">
<AU>Maksoud NA</AU>
<TI>Evolution of Techniques over 10 years and 10000 cases</TI>
<SO>3rd Berlin Stapleford International Addiction Conference</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-1973" NAME="Martin 1973" TYPE="JOURNAL_ARTICLE">
<AU>Martin WR, Jasinski DR, Mansky PA</AU>
<TI>Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1973</YR>
<VL>28</VL>
<NO>6</NO>
<PG>784-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattick-2003" MODIFIED="2008-03-27 16:13:46 +0100" MODIFIED_BY="[Empty name]" NAME="Mattick 2003" TYPE="COCHRANE_REVIEW">
<AU>Mattick RP, Breen C, Kimber J, Davoli M</AU>
<TI>Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-03-27 16:13:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-03-27 16:13:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McLellan-2000" NAME="McLellan 2000" TYPE="JOURNAL_ARTICLE">
<AU>McLellan AT, Lewis DC, O'Brien CP, Kleber HD</AU>
<TI>Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>284</VL>
<NO>13</NO>
<PG>1689-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minozzi-2006" MODIFIED="2008-03-27 16:13:26 +0100" MODIFIED_BY="[Empty name]" NAME="Minozzi 2006" TYPE="COCHRANE_REVIEW">
<AU>Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A</AU>
<TI>Oral naltrexone maintenance treatment for opioid dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-03-27 16:13:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-03-27 16:13:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moran-2007" NAME="Moran 2007" TYPE="UNPUBLISHED">
<AU>Moran W</AU>
<TI>Naltrexone Implant - Improved Long Term Extended Release Naltrexone Implant Model 2 eu</TI>
<SO>personal communication</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navaratnam-1994" NAME="Navaratnam 1994" TYPE="JOURNAL_ARTICLE">
<AU>Navaratnam V, Jamaludin A, Raman N, Mohamed M, Mansor SM</AU>
<TI>Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>1994</YR>
<VL>34</VL>
<NO>3</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OAS-2005" NAME="OAS 2005" TYPE="OTHER">
<AU>Substance Abuse and Mental Health Services Administration</AU>
<TI>Results from the 2004 National Survey on Drug Use and Health: National Findings</TI>
<SO>http://oas.samhsa.gov/nsduh/</SO>
<YR>(accessed 14 February 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Partecke-2007" NAME="Partecke 2007" TYPE="UNPUBLISHED">
<AU>Partecke G</AU>
<TI>Cravex</TI>
<SO>personal communication</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preston-1999" NAME="Preston 1999" TYPE="JOURNAL_ARTICLE">
<AU>Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR</AU>
<TI>Improvement in naltrexone treatment compliance with contingency management</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>2</NO>
<PG>127-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-San-1991" NAME="San 1991" TYPE="JOURNAL_ARTICLE">
<AU>San L, Pomarol G, Peri JM, Olle JM, Cami J</AU>
<TI>Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts</TI>
<SO>British Journal of Addiction</SO>
<YR>1991</YR>
<VL>86</VL>
<NO>8</NO>
<PG>983-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Brink-2006" NAME="van den Brink 2006" TYPE="JOURNAL_ARTICLE">
<AU>van den Brink W, Haasen C</AU>
<TI>Evidenced-based treatment of opioid-dependent patients</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>51</VL>
<NO>10</NO>
<PG>635-46</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-03-27 16:11:13 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-03-27 16:11:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Carreno-2003">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, prospective trial, 1 year observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=156, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Wedgewood naltrexone implant 1000 mg, rapid opioid detoxification with induction onto naltrexone: sequential treatment periods possible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>retention in treatment, relapse to opioid use, adverse effects, Addiction Severity Index outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: no comparison group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Comer-2002">
<CHAR_METHODS>
<P>non-RCT: dose-finding trial (phase II), 2 sequential treatment groups, 6 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent inpatients, n=12, non treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Biotek naltrexone depot 192 or 384 mg, detoxification followed by depot injections, heroin challenge protocol<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>heroin effects during blockade, opioid withdrawal symptoms, naltrexone plasma levels, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: non treatment seeking sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:08:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comer-2006">
<CHAR_METHODS MODIFIED="2008-03-27 16:08:28 +0100" MODIFIED_BY="[Empty name]">
<P>RCT: 2 centres, 3 parallel treatment groups, placebo-controlled randomised trial, 8 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=60, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Biotek naltrexone depot 192 or 384 mg, or placebo, detoxification followed by depot injections, all 3 treatment groups with manualised relapse prevention therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>retention in treatment / time to drop out, illicit drug use by urinalysis, heroin craving, depression, adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>only study included for analyses of effectiveness</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dunbar-2006">
<CHAR_METHODS>
<P>RCT: dose-finding trial (phase I), 2 sequential panels of 5 treatment groups, 2 (panel A) or 5 (panel B) months observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>healthy volunteers, outpatients<BR/>- Panel A consisted of n=28 participants in 3 treatment groups: low dose, high dose, placebo<BR/>- Panel B consisted of n=14 participants in 2 treatment groups: high dose or placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alkermes naltrexone depot 190 or 380 mg, or placebo, oral naltrexone lead-in followed by single (panel A) or multiple (panel B) depot injections.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pharmacokinetics, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: healthy volunteers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:08:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foster-2003">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, prospective trial, 12 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, seeking treatment in private clinic, first cohort n=55, second cohort n=46</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-03-27 16:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Wedgewood naltrexone implant 1000 mg, sequential treatment periods possible<BR/>- first cohort: rapid detoxification under general anaesthesia (RODA) followed by implant<BR/>- second cohort: domiciliary (i.e. non-iv sedation) rapid detoxification followed by implant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>opioid use, naltrexone plasma levels, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: no comparison group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Galloway-2005">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, prospective trial, 6 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>alcohol dependent outpatients, n=16, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DrugAbuse Sciences naltrexone depot (300mg), oral naltrexone lead-in followed by depot injection, weekly individual counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>alcohol use, alcohol craving, pharmacokinetics,<BR/>adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: alcohol dependent sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:08:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garbutt-2005">
<CHAR_METHODS MODIFIED="2008-03-27 16:08:45 +0100" MODIFIED_BY="[Empty name]">
<P>RCT: 24 centres, 3 parallel treatment groups, placebo-controlled randomised trial,24 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>alcohol dependent outpatients, n=624, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alkermes naltrexone depot 190 or 380mg, or placebo, sequentially administered monthly during 6 months, <BR/>12 sessions of manual based supportive therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>alcohol consumption, time to drop out, changes in liver enzyme levels<BR/>adverse events, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: alcohol dependent sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:08:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-G_x00f6_lz-2000">
<CHAR_METHODS>
<P>non-RCT: 2 sequential treatment groups, prospective trial, 2 year observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=108, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-03-27 16:08:49 +0100" MODIFIED_BY="[Empty name]">
<P>Wedgewood naltrexone implant 1000 mg or thrice weekly oral naltrexone, rapid opioid detoxification under anaesthesia followed by induction onto naltrexone, unclear if repeated implantations possible, free to choose groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>relapse to opioid use, abstinence, duration of receptor blockade, additional safety data provided by Partecke <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: no adequate comparison group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:08:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hulse-2005">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, retrospective record-linkage study, pre-post design, 18 months observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=361 treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-03-27 16:08:53 +0100" MODIFIED_BY="[Empty name]">
<P>GoMedical naltrexone implant 3400mg, rapid opioid detoxification with induction onto naltrexone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>hospital presentations due to opioid or other drug poisonings<BR/>implants removed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: uncontrolled, retrospective record-linkage study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:09:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2004">
<CHAR_METHODS MODIFIED="2008-03-27 16:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT: 4 centres, 2 parallel treatment groups, placebo-controlled randomised trial, 4 months observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>alcohol dependent outpatients, n=30, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-03-27 16:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Alkermes naltrexone depot 400mg or placebo, psychosocial support once monthly, manual based at the two US centres</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>alcohol consumption, pharmacokinetics, changes in liver enzymes,<BR/>adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: alcohol dependent sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:09:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-1998">
<CHAR_METHODS>
<P>RCT: 2 parallel treatment groups, placebo-controlled randomised trial, 12 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>alcohol dependent outpatients, n=20, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Biotek naltrexone depot 206mg or placebo, two weeks with oral naltrexone lead-in, weekly psychotherapy sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-27 16:09:10 +0100" MODIFIED_BY="[Empty name]">
<P>alcohol consumption, pharmacokinetics, changes in gamma GT levels,<BR/>adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: alcohol dependent sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:09:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-2004">
<CHAR_METHODS MODIFIED="2008-03-27 16:09:17 +0100" MODIFIED_BY="[Empty name]">
<P>RCT: 30 centres, 2 parallel treatment groups, placebo-controlled randomised trial, 3 months observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>alcohol dependent outpatients, n=333, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DrugAbuse Sciences naltrexone depot 300 or 150 mg, or placebo, oral naltrexone lead-in followed by sequentially administered depot injections during 3 months, 4 manual based counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>alcohol consumption,<BR/>adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: alcohol dependent sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sullivan-2006">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, dose-finding trial (phase II), 6 weeks observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent inpatients, n=5, non treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Biotek naltrexone depot 384 mg, detox and oral naltrexone lead-in followed by depot injection, heroin challenge protocol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>heroin dose effects, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: non treatment seeking sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tait-2007">
<CHAR_METHODS>
<P>two parallel treatment groups, record linkage, 5 and a half years observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=341 treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GoMedical naltrexone implant 2200 mg, methadone maintenance treatment, possibility of sequential treatment episodes not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-27 16:11:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turncliff-2005">
<CHAR_METHODS MODIFIED="2008-03-27 16:11:13 +0100" MODIFIED_BY="[Empty name]">
<P>non-RCT: 2 parallel treatment groups, matched case-control trial, 3 months observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>alcohol dependent outpatients (currently abstinent, liver impaired) and healthy controls, n=25, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alkermes naltrexone depot 190 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pharmacokinetics, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: alcohol dependent sample</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Waal-2003">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, prospective trial, 2 months observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=10, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Wedgewood naltrexone implant 1000 mg, sequential treatment periods possible, counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pharmcokinetics, drug use, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: no comparison group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Waal-2006">
<CHAR_METHODS>
<P>non-RCT: uncontrolled, prospective trial, 1 year observation period (after last implant)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients, n=13, treatment seeking</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GoMedical naltrexone implant 1800 or 3600 mg, sequential treatment periods possible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pharmacokinetics, drug use, quality of life, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>included for safety analyses only: no comparison group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Albanese-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brewer-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (comment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brewer-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>case study, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brewer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>case report, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carreno-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chiang-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>pilot study on healthy volunteers with focus on pharmacokinetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chiang-1985a">
<CHAR_REASON_FOR_EXCLUSION>
<P>pilot study on healthy volunteers with focus on pharmacokinetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chiang-1985b">
<CHAR_REASON_FOR_EXCLUSION>
<P>pilot study on healthy volunteers: concludes with recommending no further investigations on this particular product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Collins-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colquhoun-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dean-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dean-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garcia_x002d_Alonso-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gooberman-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>abstract from conference presentation only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grusser-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamilton-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harrison-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heading-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>case report, adverse effect data not provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2003c">
<CHAR_REASON_FOR_EXCLUSION>
<P>case report, adverse effect data not provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2004a">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2004c">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hulse-2004d">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iversen-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jasinski-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jeffrey-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, hepatitis C treatment-related outcomes only, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lerner-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marlowe-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (dogs)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Modesto_x002d_Lowe-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ngo-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-NRCC-report-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Brien-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (comment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Brien-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (comment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Malley-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oliver-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (letter)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pekta-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>abstract available only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pitt-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (animals) and duplicate of NIDA research monograph 28</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poser-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rabinowitz-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>oral naltrexone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramenskaya-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (pharmacokinetic results)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rawson-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reece-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>non-RCT, adverse effect data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Resnick-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reuning-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (animals)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riddle-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwope-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (mice)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sobel-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>abstract available only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suhaida-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (in vitro study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teagle-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (press release)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Warhaft-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (letter)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wesson-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>abstract available only, 9 and 12 months follow-up data from same sample as included report Kranzler 2004</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Willette-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Willette-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review and animal studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wodak-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>no clinical trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Hulse">
<CHAR_STUDY_NAME>
<P>A randomised, double-blind, placebo-controlled clinical trial of naltrexone implants for the treatment of heroin addiction</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients (DSM IV)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups: naltrexone implant + oral placebo compared to placebo implant + oral naltrexone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>naltrexone blood levels, retention in treatment, <BR/>opiate use, opiate overdose, opiate related morbidity and mortality, craving for heroin, other drug use, other drug overdose, other drug-related morbidity or<BR/>mortality, social functioning, general health, implant insertion site healing</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>recruitment and follow-up is completed</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Gary Hulse: hulseg@meddent.uwa.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: Australia</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Kun_x00f8_e">
<CHAR_STUDY_NAME>
<P>Naltrexone Implants - a Randomised Study<BR/>http://clinicaltrials.gov reference: NCT00521157</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients opting for relapse prevention with naltrexone implants compared to treatment-as-usual controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>12 months, observation 2 groups: treatment start with naltrexone implants before institutional discharge, group cross over optional after 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>drug use, quality of life, depression, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>recruitment started January 2006, completed in June 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Nikolaj Kunøe: nikolaj.kunoe@medisin.uio.no</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: <BR/>Norway</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Lobmaier">
<CHAR_STUDY_NAME>
<P>Naltrexone Implants - a Treatment Alternative for Heroin Dependent Prisoners?<BR/>http://clinicaltrials.gov reference: NCT00520793</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>opioid dependent inmates</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>18 months observation 2 groups: treatment start with naltrexone implants or methadone maintenance before prison release, cross over optional after 6 and 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>drug use, criminal activity, quality of life, depression, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>recruitment started May 2005, completed July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Philipp Lobmaier: p.p.lobmaier@medisin.uio.no</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: <BR/>Norway</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Nunes-2002">
<CHAR_STUDY_NAME>
<P>Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Clinicaltrial.gov reference: NCT00332228<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 months observation, 4 groups: 1) behavioral therapy plus depot naltrexone 2) behavioral therapy plus placebo injections 3) Compliance Enhancement (CE), simulating standard treatment with oral naltrexone plus depot naltrexone 4) CE plus placebo injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>heroin use, retention in treatment, naltrexone blood levels,</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>recruitment started June 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Stephen Anen: anenste@pi.cpmc.columbia.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: <BR/>USA</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Nunes-2008">
<CHAR_STUDY_NAME>
<P>Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-Oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 months observation, 2 groups: behavioral naltrexone therapy for depot naltrexone (depot-BNT) compared to BNT plus oral naltrexone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>opioid use, retention in treatment, medication compliance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Recruitment started September 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Yaacov Elkus: elkusya@pi.cpmc.columbia.edu and Elizabeth Martinez: martine@pi.cpmc.columbia.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: <BR/>USA</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Tiihonen">
<CHAR_STUDY_NAME>
<P>Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence: a double-blind, randomised, placebo-controlled trial<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Amphetamine and opioid dependent outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>10 weeks observation, two groups: naltrexone implant compared to placebo <BR/>implant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>amphetamine use, opioid dependence, use of benzodiazepines and cannabis</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>recruitment started November 2007, anticipated completed by December 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Jari Tiihonen: <BR/>jari.tiihonen@niuva.fi</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: <BR/>Russia</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Woody">
<CHAR_STUDY_NAME>
<P>Effectiveness of Oral and Depot Naltrexone in Treating Heroin Dependent Individuals Seeking Treatment for Heroin Addiction<BR/>clinicaltrials.gov reference NCT00218426</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>opioid dependent outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 months observation, 3 groups: 1) oral naltrexone + placebo injection, 2) oral placebo + depot naltrexone 3) oral placebo + placebo injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>opioid use, time to drop out, other drug use, psychiatric symptoms, HIV risk</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>recruitment started July 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>George Woody: <BR/>woody@tresearch.org and <BR/>Evgeny Krupitsky: kru@ek3506.spb.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Country: <BR/>Russia</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carreno-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Comer-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Comer-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dunbar-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Foster-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Galloway-2005">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-G_x00f6_lz-2000">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hulse-2005">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sullivan-2006">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tait-2007">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Turncliff-2005">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Waal-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Waal-2006">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-03-27 15:47:04 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Reports and potential sources of bias</TITLE>
<TABLE COLS="5" ROWS="18">
<TR>
<TH>
<P>report</P>
</TH>
<TH>
<P>selection bias</P>
</TH>
<TH>
<P>performance bias</P>
</TH>
<TH>
<P>attrition bias</P>
</TH>
<TH>
<P>detection bias</P>
</TH>
</TR>
<TR>
<TD>
<P>Kranzler 2004</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Garbutt 2005</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Comer 2006</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Johnson 2004</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Kranzler 1998</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Dunbar 2006</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Comer 2002</P>
</TD>
<TD>
<P>non-RCT, 2 sequential treatment groups</P>
</TD>
<TD>
<P>not applicable (N/A)</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Turncliff 2005</P>
</TD>
<TD>
<P>non-RCT, 2 matched-controlled treatment groups</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Galloway 2005</P>
</TD>
<TD>
<P>non-RCT, uncontrolled</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Gölz 2000</P>
</TD>
<TD>
<P>non-RCT, 2 sequential treatment groups</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Foster 2003</P>
</TD>
<TD>
<P>non-RCT, uncontrolled</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Hulse 2005</P>
</TD>
<TD>
<P>non-RCT, record-linkage data</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>prospectively collected data: blind to treatment allocation at outcome assessment</P>
</TD>
</TR>
<TR>
<TD>
<P>Tait 2007</P>
</TD>
<TD>
<P>non-RCT, record-linkage data</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>prospectively collected data: blind to treatment allocation at outcome assessment</P>
</TD>
</TR>
<TR>
<TD>
<P>Sullivan 2006</P>
</TD>
<TD>
<P>non-RCT, uncontrolled</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Waal 2003</P>
</TD>
<TD>
<P>non-RCT, uncontrolled</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Waal 2006</P>
</TD>
<TD>
<P>non-RCT, uncontrolled</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>loss to follow-up completely recorded</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Carreno 2003</P>
</TD>
<TD>
<P>non-RCT, uncontrolled</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>unclear or not done</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Reports according to study medication used</TITLE>
<TABLE COLS="4" ROWS="19">
<TR>
<TH>
<P>NTX formulation</P>
</TH>
<TH>
<P>Dose (mg)</P>
</TH>
<TH>
<P>Condition</P>
</TH>
<TH>
<P>Report</P>
</TH>
</TR>
<TR>
<TD>
<P>Alkermes depot (Vivitrol)</P>
</TD>
<TD>
<P>190</P>
</TD>
<TD>
<P>alcohol dependence</P>
</TD>
<TD>
<P>Turncliff 2005</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>190 and 380</P>
</TD>
<TD>
<P>healthy volunteers</P>
</TD>
<TD>
<P>Dunbar 2006</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>190 and 380</P>
</TD>
<TD>
<P>alcohol dependence</P>
</TD>
<TD>
<P>Garbutt 2005</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>alcohol dependence</P>
</TD>
<TD>
<P>Johnson 2004</P>
</TD>
</TR>
<TR>
<TD>
<P>Biotek depot (Depotrex)</P>
</TD>
<TD>
<P>192 and 384</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Comer 2002</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>192 and 384</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Comer 2006</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>206</P>
</TD>
<TD>
<P>alcohol dependence</P>
</TD>
<TD>
<P>Kranzler 1998</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>384</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Sullivan 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>DrugAbuse Sciences depot (Naltrel)</P>
</TD>
<TD>
<P>150 and 300</P>
</TD>
<TD>
<P>alcohol dependence</P>
</TD>
<TD>
<P>Kranzler 2004</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>300</P>
</TD>
<TD>
<P>alcohol dependence</P>
</TD>
<TD>
<P>Galloway 2005</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>GoMedical implant</P>
</TD>
<TD>
<P>1800 and 3600 (corrected by Tait 2007: 1100 mg and 2200 mg)</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Waal 2006</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>3600 (corrected by Tait 2007: 2200 mg)</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Hulse 2005</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>2200</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Tait 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Wedgewood implant</P>
</TD>
<TD>
<P>1000</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Foster 2003</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>1000</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Waal 2003</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>1000</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Gölz 2000</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>1000</P>
</TD>
<TD>
<P>opioid dependence</P>
</TD>
<TD>
<P>Carreno 2003</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>effectiveness outcomes treatment vs. control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.343804748140268" CI_START="0.9192744221922305" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7532467532467533" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.5242409101303318" LOG_CI_START="-0.03655482348528328" LOG_EFFECT_SIZE="0.24384304332252424" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.08829742328278214" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="1.7044479982451857">
<NAME>treatment retention in high-dose depot vs. placebo</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.343804748140267" CI_START="0.9192744221922307" EFFECT_SIZE="1.7532467532467533" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.5242409101303317" LOG_CI_START="-0.036554823485283224" LOG_EFFECT_SIZE="0.24384304332252424" ORDER="240" O_E="0.0" SE="0.3294141899094641" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="18" VAR="0.10851370851370848" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.047681762466238" CI_START="0.7810553557727884" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4839696162041619" LOG_CI_START="-0.10731818525877611" LOG_EFFECT_SIZE="0.1883257154726929" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.21184777310248215" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.24850070904888">
<NAME>treatment retention in low-dose depot vs. placebo</NAME>
<GROUP_LABEL_1>low-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.047681762466238" CI_START="0.7810553557727884" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.4839696162041619" LOG_CI_START="-0.10731818525877611" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="241" O_E="0.0" SE="0.3473253815011518" STUDY_ID="STD-Comer-2006" TOTAL_1="20" TOTAL_2="18" VAR="0.12063492063492062" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7960365838106658" CI_START="0.7189844158462394" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.2543151786482587" LOG_CI_START="-0.14328052294859586" LOG_EFFECT_SIZE="0.05551732784983142" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5841384415677147" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0" Z="0.5473497961197925">
<NAME>treatment retention in high-dose vs. low-dose depot</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>low-dose naltrexone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7960365838106658" CI_START="0.7189844158462394" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.2543151786482587" LOG_CI_START="-0.14328052294859586" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="242" O_E="0.0" SE="0.23354968324845687" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="20" VAR="0.054545454545454536" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="31.322401804150232" CI_START="10.67759819584977" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="21.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="6.680956200913734E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="3.9873708131369807">
<NAME>time to drop out in high-dose depot vs. placebo</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naltrexone</GRAPH_LABEL_2>
<CONT_DATA CI_END="31.322401804150232" CI_START="10.67759819584977" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="27.0" ORDER="243" SD_1="13.0" SD_2="19.0" SE="5.266628308260773" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.3120591846341" CI_START="1.6879408153659003" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.022561299262364408" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="2.280782857562235">
<NAME>time to drop out in high-dose vs. low-dose depot</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>low-dose naltrexone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.3120591846341" CI_START="1.6879408153659003" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="36.0" ORDER="244" SD_1="13.0" SD_2="20.0" SE="5.261351364603792" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="21.404505923522002" CI_START="-3.404505923522004" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.15501528841572498" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.422037763504253">
<NAME>time to drop out in low-dose depot vs. placebo</NAME>
<GROUP_LABEL_1>low-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naltrexone</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.404505923522002" CI_START="-3.404505923522004" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="27.0" ORDER="245" SD_1="20.0" SD_2="19.0" SE="6.328945848682508" STUDY_ID="STD-Comer-2006" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>safety outcomes treatment vs. control</NAME>
<DICH_OUTCOME CHI2="1.0406188259515265" CI_END="2.0717097760481464" CI_START="0.7052467513665128" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2087458745874589" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="3.903333760504024" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.3163289154124834" LOG_CI_START="-0.15165890569276155" LOG_EFFECT_SIZE="0.08233500485986091" METHOD="MH" NO="1" P_CHI2="0.30767792881312706" P_Q="0.0" P_Z="0.49041500957362893" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="36" WEIGHT="200.0" Z="0.6896489050127083">
<NAME>high-dose depot vs. placebo in opioid dependence</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours naltrexone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3471498611403123" CI_START="0.7922392016877886" DF="0.0" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.3705408193763955" LOG_CI_START="-0.10114367158148309" LOG_EFFECT_SIZE="0.13469857389745615" NO="1" P_CHI2="1.0" P_Z="0.2629649493424552" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="1.1194107869512155">
<NAME>one or more adverse effects</NAME>
<DICH_DATA CI_END="2.3471498611403123" CI_START="0.7922392016877886" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.3705408193763955" LOG_CI_START="-0.10114367158148309" LOG_EFFECT_SIZE="0.13469857389745615" ORDER="246" O_E="0.0" SE="0.27706980486454447" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="18" VAR="0.07676767676767673" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.377231921964285" CI_START="0.011889861865633074" DF="0.0" EFFECT_SIZE="0.2753623188405797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.8046322113416229" LOG_CI_START="-1.9248231909104756" LOG_EFFECT_SIZE="-0.5600954897844264" NO="2" P_CHI2="1.0" P_Z="0.42117445885583726" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="0.804385363450174">
<NAME>discontinued due to adverse effects</NAME>
<DICH_DATA CI_END="6.377231921964282" CI_START="0.011889861865633084" EFFECT_SIZE="0.2753623188405797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8046322113416227" LOG_CI_START="-1.9248231909104754" LOG_EFFECT_SIZE="-0.5600954897844264" ORDER="247" O_E="0.0" SE="1.6032956143050265" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="18" VAR="2.5705568268497325" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.447111296256799" CI_END="1.8135889118138586" CI_START="0.9534435662875185" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.314973262032086" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="52" I2="44.9249365978336" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2585388518732159" LOG_CI_START="-0.020705007468779218" LOG_EFFECT_SIZE="0.11891692220221833" METHOD="MH" NO="2" P_CHI2="0.14183647600960725" P_Q="0.0" P_Z="0.09505510644856117" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="640" TOTAL_2="632" WEIGHT="400.0" Z="1.6693143062691367">
<NAME>high-dose depot vs. placebo in alcohol dependence</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8094280683831236" CI_START="0.7308939344473445" DF="0.0" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.25754132293732684" LOG_CI_START="-0.13614564223010345" LOG_EFFECT_SIZE="0.06069784035361165" NO="1" P_CHI2="1.0" P_Z="0.5456000925904625" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="5" WEIGHT="100.0" Z="0.6043663700262272">
<NAME>one or more adverse effects</NAME>
<DICH_DATA CI_END="1.8094280683831234" CI_START="0.7308939344473446" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="0.2575413229373268" LOG_CI_START="-0.1361456422301034" LOG_EFFECT_SIZE="0.06069784035361165" ORDER="248" O_E="0.0" SE="0.2312536721212556" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.0534782608695652" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.477674888799776" CI_START="0.31262480863406344" DF="0.0" EFFECT_SIZE="0.6796747967479675" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.16957889310376703" LOG_CI_START="-0.50497656110453" LOG_EFFECT_SIZE="-0.16769883400038152" NO="2" P_CHI2="1.0" P_Z="0.3297987435587322" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="0.974519360386386">
<NAME>severe adverse effects</NAME>
<DICH_DATA CI_END="1.477674888799776" CI_START="0.31262480863406344" EFFECT_SIZE="0.6796747967479675" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.16957889310376703" LOG_CI_START="-0.50497656110453" LOG_EFFECT_SIZE="-0.16769883400038152" ORDER="249" O_E="0.0" SE="0.39623721290530445" STUDY_ID="STD-Garbutt-2005" TOTAL_1="205" TOTAL_2="209" VAR="0.15700392889096357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.277629984614594" CI_START="0.7281434715599187" DF="0.0" EFFECT_SIZE="1.2878048780487805" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.357483171590138" LOG_CI_START="-0.13778303996198438" LOG_EFFECT_SIZE="0.10985006581407677" NO="3" P_CHI2="1.0" P_Z="0.38460642181056903" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="0.8694401825644692">
<NAME>injection site pain</NAME>
<DICH_DATA CI_END="2.277629984614594" CI_START="0.7281434715599187" EFFECT_SIZE="1.2878048780487805" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.357483171590138" LOG_CI_START="-0.13778303996198438" LOG_EFFECT_SIZE="0.10985006581407677" ORDER="250" O_E="0.0" SE="0.29092182427300284" STUDY_ID="STD-Garbutt-2005" TOTAL_1="205" TOTAL_2="209" VAR="0.08463550783833196" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8791697999330292" CI_START="1.1497038468642056" DF="0.0" EFFECT_SIZE="2.1118466898954704" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.5887387900563511" LOG_CI_START="0.06058598449568437" LOG_EFFECT_SIZE="0.32466238727601776" NO="4" P_CHI2="1.0" P_Z="0.015968678747594913" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="2.409630620139526">
<NAME>discontinued due to adverse effects</NAME>
<DICH_DATA CI_END="3.8791697999330292" CI_START="1.1497038468642056" EFFECT_SIZE="2.1118466898954704" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5887387900563511" LOG_CI_START="0.06058598449568437" LOG_EFFECT_SIZE="0.32466238727601776" ORDER="251" O_E="0.0" SE="0.3102395723848877" STUDY_ID="STD-Garbutt-2005" TOTAL_1="205" TOTAL_2="209" VAR="0.09624859227355796" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14742397589048484" CI_END="2.290246340973472" CI_START="0.7482684188182329" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3090909090909093" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.35988219796065785" LOG_CI_START="-0.12594258408660847" LOG_EFFECT_SIZE="0.11696980693702469" METHOD="MH" NO="3" P_CHI2="0.9289392180599735" P_Q="0.0" P_Z="0.34528051104369484" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="54" WEIGHT="300.0" Z="0.9437830977212983">
<NAME>low-dose depot vs. placebo in opioid dependence</NAME>
<GROUP_LABEL_1>low-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours naltrexone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2824470876732814" CI_START="0.7404333748313877" DF="0.0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.35840071838689497" LOG_CI_START="-0.13051401377322142" LOG_EFFECT_SIZE="0.11394335230683678" NO="1" P_CHI2="1.0" P_Z="0.36095155351835606" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.9135534362503995">
<NAME>one or more adverse effects</NAME>
<DICH_DATA CI_END="2.2824470876732814" CI_START="0.7404333748313877" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.35840071838689497" LOG_CI_START="-0.13051401377322142" LOG_EFFECT_SIZE="0.11394335230683678" ORDER="252" O_E="0.0" SE="0.28719093383780847" STUDY_ID="STD-Comer-2006" TOTAL_1="20" TOTAL_2="18" VAR="0.08247863247863249" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.214927333997434" CI_START="0.1778760870460718" DF="0.0" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.2604274430219706" LOG_CI_START="-0.7498824328153585" LOG_EFFECT_SIZE="0.25527250510330607" NO="2" P_CHI2="1.0" P_Z="0.6186539194947422" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.49775899950489283">
<NAME>discontinued due to adverse effects</NAME>
<DICH_DATA CI_END="18.214927333997434" CI_START="0.1778760870460718" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2604274430219706" LOG_CI_START="-0.7498824328153585" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="253" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Comer-2006" TOTAL_1="20" TOTAL_2="18" VAR="1.3944444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.360609146112969" CI_START="0.06062597828749859" DF="0.0" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="1.1258262592446688" LOG_CI_START="-1.217341240366019" LOG_EFFECT_SIZE="-0.045757490560675115" NO="3" P_CHI2="1.0" P_Z="0.9389826924711028" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.07654854681686679">
<NAME>injection site induration</NAME>
<DICH_DATA CI_END="13.360609146112969" CI_START="0.06062597828749859" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1258262592446688" LOG_CI_START="-1.217341240366019" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="254" O_E="0.0" SE="1.3763881881375053" STUDY_ID="STD-Comer-2006" TOTAL_1="20" TOTAL_2="18" VAR="1.8944444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.7693357913762435" CI_END="1.2316660943550692" CI_START="1.0523558177694736" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1384862669105686" ESTIMABLE="YES" EVENTS_1="734" EVENTS_2="619" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.09049298620996983" LOG_CI_START="0.022162606325763553" LOG_EFFECT_SIZE="0.0563277962678667" METHOD="MH" NO="4" P_CHI2="0.9136439904754291" P_Q="0.0" P_Z="0.0012319731357528175" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2418" TOTAL_2="2355" WEIGHT="800.0" Z="3.231372405674158">
<NAME>low-dose depot vs. placebo in alcohol dependence</NAME>
<GROUP_LABEL_1>low-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.028087811003907566" CI_END="1.1719163550853102" CI_START="0.9528937625395041" DF="1.0" EFFECT_SIZE="1.0567458469181805" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="134" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.0688966152475569" LOG_CI_START="-0.020955515851427037" LOG_EFFECT_SIZE="0.023970549698064905" NO="1" P_CHI2="0.8669025737353353" P_Z="0.29567668132557523" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="171" WEIGHT="100.0" Z="1.0457495781837047">
<NAME>one or more adverse effect</NAME>
<DICH_DATA CI_END="3.8817349780849906" CI_START="0.35064503857051044" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.5890258810048754" LOG_CI_START="-0.4551323017436491" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="255" O_E="0.0" SE="0.6133436852128471" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.37619047619047613" WEIGHT="2.21571628185508"/>
<DICH_DATA CI_END="1.167423986999812" CI_START="0.9520567362921346" EFFECT_SIZE="1.0542551261114135" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="132" LOG_CI_END="0.06722861249190018" LOG_CI_START="-0.02133716976218027" LOG_EFFECT_SIZE="0.02294572136485995" ORDER="256" O_E="0.0" SE="0.052023978903739575" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.00270649438097674" WEIGHT="97.78428371814492"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0357071003418765" CI_START="0.48656256395962244" DF="0.0" EFFECT_SIZE="0.9952380952380953" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.30871529141717285" LOG_CI_START="-0.31286130866290346" LOG_EFFECT_SIZE="-0.0020730086228652584" NO="2" P_CHI2="1.0" P_Z="0.9895693294294476" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="209" WEIGHT="100.0" Z="0.013073279270594977">
<NAME>discontinued due to adverse effects</NAME>
<DICH_DATA CI_END="2.0357071003418765" CI_START="0.4865625639596225" EFFECT_SIZE="0.9952380952380953" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.30871529141717285" LOG_CI_START="-0.3128613086629034" LOG_EFFECT_SIZE="-0.0020730086228652584" ORDER="257" O_E="0.0" SE="0.36511717174083" STUDY_ID="STD-Garbutt-2005" TOTAL_1="210" TOTAL_2="209" VAR="0.13331054910002277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0068106093524067" CI_END="1.4749491771147787" CI_START="0.9219305759713816" DF="2.0" EFFECT_SIZE="1.1661049456999757" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="83" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.16877705592172415" LOG_CI_START="-0.03530178134086165" LOG_EFFECT_SIZE="0.06673763729043125" NO="3" P_CHI2="0.6044688161977779" P_Z="0.19988104675291535" STUDIES="3" TAU2="0.0" TOTAL_1="392" TOTAL_2="380" WEIGHT="100.0" Z="1.2818905405094936">
<NAME>injection site pain</NAME>
<DICH_DATA CI_END="1.7449522395441923" CI_START="0.5094578359743241" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.24178354454088913" LOG_CI_START="-0.29289175348566543" LOG_EFFECT_SIZE="-0.025554104472388164" ORDER="258" O_E="0.0" SE="0.31407091674620863" STUDY_ID="STD-Garbutt-2005" TOTAL_1="210" TOTAL_2="209" VAR="0.0986405407458039" WEIGHT="22.610708310427"/>
<DICH_DATA CI_END="3.0279465654077513" CI_START="0.2293450130124501" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.48114820684080994" LOG_CI_START="-0.6395106989360596" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="259" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.4333333333333333" WEIGHT="3.561611572206359"/>
<DICH_DATA CI_END="1.6138872329496943" CI_START="0.9689823671840849" EFFECT_SIZE="1.2505311956731697" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="62" LOG_CI_END="0.2078731860126743" LOG_CI_START="-0.013684125843277687" LOG_EFFECT_SIZE="0.09709453008469832" ORDER="260" O_E="0.0" SE="0.13014386171056766" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.016937424740939358" WEIGHT="73.82768011736664"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6885226395925582" CI_END="1.7965993993587053" CI_START="0.7635547202416222" DF="1.0" EFFECT_SIZE="1.171239493768718" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="30" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="0.25445125015118164" LOG_CI_START="-0.11715983372555008" LOG_EFFECT_SIZE="0.0686457082128158" NO="4" P_CHI2="0.4066677283785516" P_Z="0.46899997941071836" STUDIES="2" TAU2="0.0" TOTAL_1="182" TOTAL_2="171" WEIGHT="100.0" Z="0.7241071196627391">
<NAME>injection site induration</NAME>
<DICH_DATA CI_END="5.596739265121769" CI_START="0.6005480962919187" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="0.7479350749330893" LOG_CI_START="-0.22145220538392646" LOG_EFFECT_SIZE="0.2632414347745814" ORDER="261" O_E="0.0" SE="0.5694228870026425" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.3242424242424243" WEIGHT="9.651241425949184"/>
<DICH_DATA CI_END="1.7496645398000092" CI_START="0.6922066522559827" EFFECT_SIZE="1.100513259195894" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.2429547901267705" LOG_CI_START="-0.15976423135771992" LOG_EFFECT_SIZE="0.04159527938452528" ORDER="262" O_E="0.0" SE="0.23655914671129663" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.05596022989277677" WEIGHT="90.34875857405082"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.57332762735813" CI_START="0.599940495104337" DF="0.0" EFFECT_SIZE="1.2425149700598803" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-002.04.05" LOG_CI_END="0.4104950826330586" LOG_CI_START="-0.22189182283200212" LOG_EFFECT_SIZE="0.09430162990052825" NO="5" P_CHI2="1.0" P_Z="0.5588568999979475" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="166" WEIGHT="100.0" Z="0.5845402448759989">
<NAME>injection site contusion</NAME>
<DICH_DATA CI_END="2.57332762735813" CI_START="0.599940495104337" EFFECT_SIZE="1.2425149700598803" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.4104950826330586" LOG_CI_START="-0.22189182283200212" LOG_EFFECT_SIZE="0.09430162990052825" ORDER="263" O_E="0.0" SE="0.3714671986358446" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.13798787966236203" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3785867960818816" CI_START="1.022080006040826" DF="0.0" EFFECT_SIZE="1.1870240102319634" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="103" I2="0.0" ID="CMP-002.04.06" LOG_CI_END="0.13943411456420318" LOG_CI_START="0.009484892689192038" LOG_EFFECT_SIZE="0.07445950362669758" NO="6" P_CHI2="1.0" P_Z="0.02469910958627519" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="166" WEIGHT="100.0" Z="2.2460764798641746">
<NAME>one or more injection site reaction</NAME>
<DICH_DATA CI_END="1.3785867960818816" CI_START="1.022080006040826" EFFECT_SIZE="1.1870240102319634" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="103" LOG_CI_END="0.13943411456420318" LOG_CI_START="0.009484892689192038" LOG_EFFECT_SIZE="0.07445950362669758" ORDER="264" O_E="0.0" SE="0.07633281618840418" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.005826698827252699" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5514023739848293" CI_START="0.34334630918176356" DF="0.0" EFFECT_SIZE="0.7298412698412698" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-002.04.07" LOG_CI_END="0.190724451674186" LOG_CI_START="-0.46426761671482897" LOG_EFFECT_SIZE="-0.13677158252032148" NO="7" P_CHI2="1.0" P_Z="0.4130510592652694" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="209" WEIGHT="100.0" Z="0.8185362503936969">
<NAME>severe adverse effect</NAME>
<DICH_DATA CI_END="1.5514023739848293" CI_START="0.34334630918176356" EFFECT_SIZE="0.7298412698412698" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.190724451674186" LOG_CI_START="-0.46426761671482897" LOG_EFFECT_SIZE="-0.13677158252032148" ORDER="265" O_E="0.0" SE="0.38474558323473645" STUDY_ID="STD-Garbutt-2005" TOTAL_1="210" TOTAL_2="209" VAR="0.1480291638186375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6306230477427477" CI_END="1.3639051711493209" CI_START="1.0211573935557532" DF="2.0" EFFECT_SIZE="1.1801533161534792" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="228" I2="0.0" ID="CMP-002.04.08" LOG_CI_END="0.13478417598157522" LOG_CI_START="0.009092686146268052" LOG_EFFECT_SIZE="0.07193843106392162" NO="8" P_CHI2="0.7295616097087391" P_Z="0.02486222719590519" STUDIES="3" TAU2="0.0" TOTAL_1="908" TOTAL_2="883" WEIGHT="100.0" Z="2.2435366813513156">
<NAME>injection site related to adverse effects, pooled</NAME>
<DICH_DATA CI_END="1.7449522395441923" CI_START="0.5094578359743241" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.24178354454088913" LOG_CI_START="-0.29289175348566543" LOG_EFFECT_SIZE="-0.025554104472388164" ORDER="266" O_E="0.0" SE="0.31407091674620863" STUDY_ID="STD-Garbutt-2005" TOTAL_1="210" TOTAL_2="209" VAR="0.0986405407458039" WEIGHT="8.256857130712474"/>
<DICH_DATA CI_END="3.056581906511635" CI_START="0.5816228166470729" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.4852360379695516" LOG_CI_START="-0.23535856475295178" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="267" O_E="0.0" SE="0.4232808366400098" STUDY_ID="STD-Kranzler-1998" TOTAL_1="30" TOTAL_2="10" VAR="0.17916666666666667" WEIGHT="2.601220404337238"/>
<DICH_DATA CI_END="1.3926673151641575" CI_START="1.0299639758643593" EFFECT_SIZE="1.1976632101650357" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="205" LOG_CI_END="0.14384738315450976" LOG_CI_START="0.012822035038256668" LOG_EFFECT_SIZE="0.07833470909638324" ORDER="268" O_E="0.0" SE="0.07696493806942048" STUDY_ID="STD-Kranzler-2004" TOTAL_1="668" TOTAL_2="664" VAR="0.005923601692029729" WEIGHT="89.14192246495028"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09482201919920258" CI_END="13.62958316962563" CI_START="0.2626092732302242" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8918918918918919" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.1344825741105644" LOG_CI_START="-0.5806899422160409" LOG_EFFECT_SIZE="0.27689631594726183" METHOD="MH" NO="5" P_CHI2="0.7581342162256114" P_Q="0.0" P_Z="0.5268442904091608" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="12" WEIGHT="200.0" Z="0.6328305771489101">
<NAME>low-dose depot vs. placebo in healthy volunteers</NAME>
<GROUP_LABEL_1>low-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="38.88518380215695" CI_START="0.15555901351787066" DF="0.0" EFFECT_SIZE="2.4594594594594597" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.589784156115468" LOG_CI_START="-0.8081048196072707" LOG_EFFECT_SIZE="0.39083966825409866" NO="1" P_CHI2="1.0" P_Z="0.5228738617280497" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="6" WEIGHT="100.0" Z="0.6389217192816272">
<NAME>one or more adverse effects</NAME>
<DICH_DATA CI_END="38.88518380215695" CI_START="0.15555901351787066" EFFECT_SIZE="2.4594594594594597" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.589784156115468" LOG_CI_START="-0.8081048196072707" LOG_EFFECT_SIZE="0.39083966825409866" ORDER="269" O_E="0.0" SE="1.4085318540813991" STUDY_ID="STD-Dunbar-2006" TOTAL_1="36" TOTAL_2="6" VAR="1.9839619839619838" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.916222880140555" CI_START="0.07653246022131205" DF="0.0" EFFECT_SIZE="1.3243243243243243" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="1.3601430374885741" LOG_CI_START="-1.1161543255655368" LOG_EFFECT_SIZE="0.12199435596151867" NO="2" P_CHI2="1.0" P_Z="0.8468692462665959" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="6" WEIGHT="100.0" Z="0.1931145649703711">
<NAME>one or more injection site reaction</NAME>
<DICH_DATA CI_END="22.916222880140545" CI_START="0.07653246022131208" EFFECT_SIZE="1.3243243243243243" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.360143037488574" LOG_CI_START="-1.1161543255655366" LOG_EFFECT_SIZE="0.12199435596151867" ORDER="270" O_E="0.0" SE="1.454589328927624" STUDY_ID="STD-Dunbar-2006" TOTAL_1="36" TOTAL_2="6" VAR="2.1158301158301156" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5394055337205546" CI_END="1.416435018218184" CI_START="0.5839439354228703" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9094606307087137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="35.03985934212393" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.15119665518782938" LOG_CI_START="-0.23362884758844685" LOG_EFFECT_SIZE="-0.04121609620030872" METHOD="MH" NO="6" P_CHI2="0.2147067682482987" P_Q="0.0" P_Z="0.6746042617847648" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="40" WEIGHT="200.0" Z="0.41983737331934096">
<NAME>high-dose vs. low-dose depot in opioid dependence</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>low-dose naltrexone</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours high-dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours low-dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6125254820346167" CI_START="0.6823447538374376" DF="0.0" EFFECT_SIZE="1.048951048951049" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.20750658632719998" LOG_CI_START="-0.1659961431459611" LOG_EFFECT_SIZE="0.020755221590619436" NO="1" P_CHI2="1.0" P_Z="0.8275639181856989" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0" Z="0.21782698544742685">
<NAME>one or more adverse effects</NAME>
<DICH_DATA CI_END="1.6125254820346167" CI_START="0.6823447538374376" EFFECT_SIZE="1.048951048951049" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.20750658632719998" LOG_CI_START="-0.1659961431459611" LOG_EFFECT_SIZE="0.020755221590619436" ORDER="271" O_E="0.0" SE="0.21939735216086387" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="20" VAR="0.04813519813519812" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5886283604643068" CI_START="0.009292111742513761" DF="0.0" EFFECT_SIZE="0.1826086956521739" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.5549284849822533" LOG_CI_START="-2.031885576221638" LOG_EFFECT_SIZE="-0.7384785456196924" NO="2" P_CHI2="1.0" P_Z="0.2631174367492456" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0" Z="1.119053258970231">
<NAME>discontinued due to adverse effects</NAME>
<DICH_DATA CI_END="3.5886283604643068" CI_START="0.009292111742513761" EFFECT_SIZE="0.1826086956521739" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5549284849822533" LOG_CI_START="-2.031885576221638" LOG_EFFECT_SIZE="-0.7384785456196924" ORDER="272" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Comer-2006" TOTAL_1="22" TOTAL_2="20" VAR="2.308902691511387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.603631076106706" CI_END="2.174162591825036" CI_START="1.036055536855301" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.500850822461713" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="43" I2="23.18420154246027" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.337292019093427" LOG_CI_START="0.015383036010893346" LOG_EFFECT_SIZE="0.17633752755216014" METHOD="MH" NO="7" P_CHI2="0.27203758904476927" P_Q="0.0" P_Z="0.03177058059584329" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="615" TOTAL_2="630" WEIGHT="300.0" Z="2.1472852345749036">
<NAME>high-dose vs. low-dose depot in alcohol dependence</NAME>
<GROUP_LABEL_1>high-dose naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>low-dose naltrexone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.898010936604518" CI_START="1.1551216892971283" DF="0.0" EFFECT_SIZE="2.1219512195121952" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.5908430532783522" LOG_CI_START="0.06262773851941388" LOG_EFFECT_SIZE="0.32673539589888306" NO="1" P_CHI2="1.0" P_Z="0.015319799952934735" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="210" WEIGHT="100.0" Z="2.42472942583462">
<NAME>discontinued due to adverse effects</NAME>
<DICH_DATA CI_END="3.898010936604518" CI_START="1.1551216892971283" EFFECT_SIZE="2.1219512195121952" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5908430532783522" LOG_CI_START="0.06262773851941388" LOG_EFFECT_SIZE="0.32673539589888306" ORDER="273" O_E="0.0" SE="0.31027629059737794" STUDY_ID="STD-Garbutt-2005" TOTAL_1="205" TOTAL_2="210" VAR="0.09627137650686851" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.439558979194332" CI_START="0.7647104384227178" DF="0.0" EFFECT_SIZE="1.3658536585365855" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.3873113221527387" LOG_CI_START="-0.11650298157980876" LOG_EFFECT_SIZE="0.13540417028646495" NO="2" P_CHI2="1.0" P_Z="0.29210624966599974" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="210" WEIGHT="100.0" Z="1.0535123562465671">
<NAME>injection site pain</NAME>
<DICH_DATA CI_END="2.439558979194332" CI_START="0.7647104384227178" EFFECT_SIZE="1.3658536585365855" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.3873113221527387" LOG_CI_START="-0.11650298157980876" LOG_EFFECT_SIZE="0.13540417028646495" ORDER="274" O_E="0.0" SE="0.29594301593352335" STUDY_ID="STD-Garbutt-2005" TOTAL_1="205" TOTAL_2="210" VAR="0.08758226867982964" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.145249839889401" CI_START="0.4042663736710528" DF="0.0" EFFECT_SIZE="0.9312638580931264" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="0.33147787823019964" LOG_CI_START="-0.39333238119031977" LOG_EFFECT_SIZE="-0.030927251480060067" NO="3" P_CHI2="1.0" P_Z="0.8671645707268851" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="210" WEIGHT="100.0" Z="0.16726115077397805">
<NAME>severe adverse effects</NAME>
<DICH_DATA CI_END="2.145249839889401" CI_START="0.4042663736710528" EFFECT_SIZE="0.9312638580931264" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.33147787823019964" LOG_CI_START="-0.39333238119031977" LOG_EFFECT_SIZE="-0.030927251480060067" ORDER="275" O_E="0.0" SE="0.42575713425226164" STUDY_ID="STD-Garbutt-2005" TOTAL_1="205" TOTAL_2="210" VAR="0.18126913736669834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.239593304455946" CI_START="1.1431780222302708" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.9656528554714302" LOG_CI_START="0.058113866486318555" LOG_EFFECT_SIZE="0.5118833609788743" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.027037576912432887" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="2.2109748759683723">
<NAME>one or more adverse effects in liver impaired vs. healthy controls</NAME>
<GROUP_LABEL_1>liver impairment</GROUP_LABEL_1>
<GROUP_LABEL_2>healthy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.239593304455946" CI_START="1.143178022230271" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9656528554714302" LOG_CI_START="0.05811386648631864" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="276" O_E="0.0" SE="0.5330928945203023" STUDY_ID="STD-Turncliff-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.2841880341880342" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6557762297708605" CI_START="0.2541322863460416" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6486803519061584" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.21900164359482358" LOG_CI_START="-0.5949401563144976" LOG_EFFECT_SIZE="-0.18796925635983705" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.36532962989453066" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="341" TOTAL_2="553" WEIGHT="100.00000000000001" Z="0.9052563038465428">
<NAME>mortality in naltrexone implant vs. methadone maintenance</NAME>
<GROUP_LABEL_1>naltrexone implant</GROUP_LABEL_1>
<GROUP_LABEL_2>methadone</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours naltrexone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours methadone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6557762297708605" CI_START="0.2541322863460416" EFFECT_SIZE="0.6486803519061584" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.21900164359482358" LOG_CI_START="-0.5949401563144976" LOG_EFFECT_SIZE="-0.18796925635983705" ORDER="277" O_E="0.0" SE="0.47811344234362496" STUDY_ID="STD-Tait-2007" TOTAL_1="341" TOTAL_2="553" VAR="0.22859246374967077" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAQQCAAAAADuBDPOAAAt8UlEQVR42u2dzZXbPJOF7+y87OUs
HUKHMKG8ITiDDuUN5Vt6OSF46eWEgLG7RRIFFPgnkgLAp85pu0WJUuHW01ARRAEKGNaRCQkwgMYw
gMYwgMYwgMYAGsMAGsMAGsMAGsMAGgNoDANoDANoDANoDANoDKAxDKAxDKAxDKAxDKAxgMYwgMYw
gMYwgMYwgMYAGsMAGsMAGsMAGsMAGgNoDAPol7Rpss/fV5+0TSc5p2jV+xY+SuXjgHrvHvqBwN9/
V9OwFeivP5dV3K/9KIAG6Hk4DwNaWvV66SkcIRegZ8iQ7awf3fWQhkzwPL7p44OaXj4lMNnLJ/w+
XxecTOfxnlL67iE/Mrog8zh6r/GDU+/TJ5S8cfxBw1+5ALphoL/wjB8FRb1qTG8Y8ZhoMezGL8je
Ijpz5Hl6aNyL+YvOj/9JnV5FtHnp+BM/Hp8H6KYuCw08UResuINSkaaIK4OPQdb8/aRAK6Xcf5N5
F2Y8898sa61peQiyzgB0gz10RnUCdJkyJcltCWjF3wYFoJM/gPyd8uNa8qzobZZBRe+ojpP1WwId
5oE2SfQaoOOct4Sesh59EWjztk8CnV8AAHSDoxyh9N2fPB9C3p1uAdpmyocBHb/tMUD3TzRAH5Fy
FD4heY+wNeWYTez3AC0zzgHQzQIdXdd76YLDTp5yaN0oh4IZd5uG98pA5y5oYZQjlEY5PB/N3wej
HM2OcZhkOPqOVdrsbIg65MPP/pf2yFTIrgpjolOp8/Hq2IX4ujU+bD9YpltPPfLGoRWiAQ5yaKxW
pbm9CNAvSYEAGqCfSzmwBQNobP/f2Kl/vQgM0BhAYxhAYxhAYxhAYxhAYwCNYQCNYQCNYQCNATSG
ATSGATSGATSGATQG0BgG0BgG0BjWNdDvFPh92jtA9gE03xPoANBEAwNoooGEBBIdkJBAogNAEw0k
6A3o9YtUKfldpzTz2mWJALrDHlrbvVpc73g3lbpWIoDuFOj4gFY4fUAPrRrkAWiABmisFaDt4vbh
a+X56VCU4j6ANjtSKt7qO19fP3oq3kLNnif3hdODYJfufzrjBuiec2hNv5vtFB4/9jn7E+K9Wws/
0R9BSDfFdF+v9IGy93pWT4DuEWjTqQ70WphDDK4P9NgpTy+QhdWeq7DmvPRNoj1NjticFaB7TTmc
Xjp4QD+2eogOys3FTZIt79zl87wnlPgsgAboJ4BWfnA10E4G8jTQpBwAXQR6gllJqvp1YMxm8yzC
8legXmnKoYXzvCfIoQF63guz/Z8Z6zDjE+ZIPLqR7hCbbcJtxjyic81urt4oh7cVofsxAA3Q6qw9
AA3QEAHQAJ2+jYgGQOMF0UBCAokOSEgg0QGgiQYG0EQDCWvxQguOTTdF9jTl9OZON1qk/PBS+wC6
2x56vqLKO2XNmN0V43rympTM3y7dUwToflOOuUOL1SUqvdMVQKvgguihAbpFoLMiMoC+fQ4tJRVW
U5WUvBKs6YzhC30saknLqE5vsimGeazKANC3BVrezM643sktwQrJOgYyeWvIy1lObou8HBqg79pD
Txg69U52ZrKpjnKuGk2R4QuBnr5BAPrOQDuMeKyuADqqt7qiLbIphzP6AdAA/QTQF6cc3gAhQN/3
ojDKm0NaJeWyOi0zEI00KOotdW3KEbyUA6DveVGobJQjrpJ6/K6sqkrxhWFUvBVCUqt1bpOltBbM
9tfzd1YAur8euofm3NV9JDzaCypWABoviAYSEkh0QEICiQ4ATTQwgCYaSIgX6ICEp3ghiWhg3QCt
O8cVoPsEmmhgAE00sFDn+tDRdlePZ+3OmornHmmaSJet19wcIADdaQ6tZMegB7fjK5wJ0llti4gG
QNeScth/0g3bQvlZuysV0QDoBoAO0iLQRAOg2wF6pqAboAG6WqBdbN0cOlqngxwaoOsb5ZDiSlPZ
fa6SZ6fqK2/vbaIB0AQSHZCQQKIDEpZSjiONaAA0gUQHJCSQ6ICEBBIdAJpoYABNNJDwNV7IzBKd
lsCP16W1v8X7Tr1+bKOwC1a+n4brJUB32EMnCy4O//hTNbKjr79B6O+CJdnmqeJoAPTZQE+/yAVa
oQ6W54gdOZ9zE6B7BDpaA9/5pnZ7aNUEtO8IQAN0MdvIUw53Xf+XtSXbBSskEwgV2HjzRkAPMTdX
V/NAx1u16uVAO5sGJRNhC+uuA3S3QCts6qHdrVmqA9ptEUDfDuiwAuiF5PTqtshNOcaHAH0voEO6
+aC8UY70NfKGQV7VFqnURHroGwKdRL2cd7QyDp1+1ZBD3wVoTSvNzN4pHDbwtl/qVdwpdKu/lOzr
xijHbXpoooEBNNHAAJpoICGBRAckJJDoANBEAwNoooGEeEE0kPA8L+JbKdGxkNwwsc/VcEcl8ifk
k/7S+yqUYN2nh46m8gyhH4+nU5Wi11WzOKN363u6d6/ZBX8Buleggw90UvcRqqq9Crm72R/pwuwp
gO4aaDMvdAboulgozmMF6PsCrQLQstCYrbFqaUyhBCv5OmFy0n2AVrIJVkiX48g3XAkV7RNUqFix
k1yZPnrLHjouXUnzUDlf5TUDrSydZpTjdjl0DrRbCVvZReGYE8UphwJA3xpopbVYWUesUOi7q2hL
aSGw2oB+V5X23hvQzjob8vIOl+oq2rI4bFdHDl3pd4K6AdoWXY21WFENVvyfQrJU4+tb4pZgmTUl
vR4coHsFmgQQ5QEaoAEaoAEaoAEaoAEaoAEaoAEaoAEaoAEaoAF6yYMDZslo4YAAGqBP+UTnfs8B
d6vypVi18BF9AT3dBLSbtkUvNbcPa9qjfqGmcMHVanvoJ329dw897WzlbeWWLOJZX/8+X1M47y1A
dwh0Oonf1ugpqHagZ2oKl9x9MdCPL8ahACGtTjbTUcYFje0Xz/hkMM+H8W2HjzHTWnoGWnmnpraA
nqkprBtoTaU0A4/R4bhyIflR1g2VX5t8zPT2vQOddmwNAV2uKawa6ERtBY/GYPLBeMuYYK4dlNSA
elDPbDfTOdC2bMWs419nDl2sKdT8qEETQEveofTtFJaADjNd0h2BrvmisFxT6CWMbQFd6LSTt1vR
Q98ZaKf0u+5RjnJNYcWjHIpXVgsqQD2l1NqaQ49SyPbykvoFOh/liL7U/BpChZqwXqgprHnYbhx+
CNEox7TQYDyCMVAtmUEOf5Rj+DfccZRjedM2/9e6qr7LTar8xkolZHR4p7CwaVt8PNn6rY6WzNYU
Lnl5XSN+AXSd/vdl1+nw8f3f+U98bRcB0AC9EWjpE2mmjwJ0L0B/Ig3QAH12Bn6lfQdogO6nh9Y/
vwAaoLsB+p9f5NAA3Q3Qf3FO5hWNWU+SBdlRDwE0QFenw39+5Z84e0tI6bZHAL3eCxWvmIpbl6y7
3hrPOK3ZS9u6zd8CevFcjtIcAl0+x6C3O4XF1zhTwbXjQ87sZdx927TuBv2rJyeVp74B9F4vSkXz
xf39tC9257VF81/cNQPtliZ4C3MD9LNAl69IqgPa6eeS2Sj1Au2kY7YsEKA3ejEuYRBmLq3Ns+M0
x2CqMpVdwtjNW8boRLMcw2PW41MXPl4/p9nvmLqBjrI9gN7bQ8utk8iRiQoupXTGuErbKcdVmtFZ
0TesnmyLvBx6xbDX64HOSxOyGAD0rpRD2chE9v2dnzB233Ef6ffQzlnH7A9X+uIObQDtLp4E0AcB
XXxFEeiktsf9kBzooUYjToKfaovTzym0AXSpfIQbK4cCHfK1ADygnZq2NC4O0Ere8Hmg55aaqBTo
cmmCbc8ld1a6Alo+1Ep7Z6cQs7QoSjZ2puwN5RTlP9OW4iqIdS8FVon1BLSyssyks7CjHMpOiA+Y
NaoULV+VLmtVyNe3t6TQz6VNAOi7AH1rbwAaoLtyBqAB+nBXFAAaoPuUFaABGqABGqABGqABGqAB
GqABGqCv9X92nbpsXyw7WaKGBe4KJVjx+tDRywD6Bj307Gw3fz3SqtYg9UuwFM8kWSrLAeju1ofW
LNDeYueqpT2Fuo5sKsqGHdQAunOgnS5Z1TSoUGo64/Iro/GmKu2tR6DlzDLK9sXyJ+W9uC1rSk0r
AZrr6styaKU72LjTl7M9TGoAurhp0FJtIUD3CLTS/VSU9GqlbZqaAloBoO/TQ0dXV/n+YN4Gs5UB
7ZRgrRqOAeiegR6rsV2gg2od5YjHOko9tAJA3w1oxYN0WQ6d93RVj0PbisaKhu0A+mQvzI0/0+Op
sC+W0uT7tS0p7NccbcoXyvdDAbrDHvrOQQbo/oEW0cD6AVoiGlhfKQfRwACaaCAhXqADEhJIdEBC
AokOtwHallglpUzZQv/hMcm0Ij3nd/tbEBygO+yhk9kZ5aeme+I1riRW2DRIAA3Q04FsKXnVx8Hc
bn/00ADtAJ1OX6pN0fJufwAN0DNAh1DjrcS5EiyABmh7Seh0frUhPbvbH0AD9BLQNS6XLnJogF4G
ujDVuMb10su7/QH0PYFORjDsw7pHOUqJEEDfGGiFjGClVIxD0FXu0MIoB0CPecV0j9A8DPG2edOe
3pWNQs/t9rd0ZwWgO+yhiQYG0EQDA2iigYQEEh2QkECiA0ATDQygiQYS4gXRQMLzvNB0ByXIFmQ9
bk+Y5ez8d9P6hRt1sBzlEqzxcHyDCKD776ELt7W9pZXLe6Np5bRSHT8VtVSCpXReCos13gdoJb8V
gJ5fBv8lPbRfguVO8QfouwEdwtJ06CqBLvW/WnYPoLtNOeQCHX1vPxKSOEmw85aCsldpWvhg3F0r
mLWb4wR457SnQglWCCqnJADdO9DON/eQVivJk5WQ5GwBoPJGQ3aHLTmH97RFM1UIc3sjA3S/QHv5
hdLd3NwdKmS/+2dhjrYBSJ/Wzh0B5nbBKmRTAH0LoNM+8oFzaZuVHGgVgH78adgcJgf6mbZkJVgK
AM0ox5NAe3sdrgA66Kk6GLcESwGgbw20W+Ht78e5mEPn3a4U5+g2zQhJorK3LYVhu1meAbo/oB8F
V2G6oeZv3DbdeiuNcowjFeOIhh07sS+KRjnim5XbW1IswTL740qMctylh67DF91eB4AGaIAGpQoD
qdft4AnQAE00MIAmGkhIINEBCQkkOgA00cA6AlrLr1Tx4YrbyTq37YUSrJW3aQC6O6C1CegVkJRf
ctLYnJb+jgD6jj30TNWHtrlfnpNxEtDenRkFgAboRoF2N4IB6PsCPa5VMM5TsojHs5KmmXJKp39G
Lxlm8Cc1V+n0pmlW0vDEnluGXgmWVuY3AN0h0DITQZVWWTmVJdOr5FdWRRRLbglWcA7tnD/q1Qdo
ZcEAQPeZcmRIyQM6BLeiKr1mTM6R80z5k48CekN6hAG0D/QwvTkHOnomSKVPnooSt7dFacoB0AD9
JNDZIa9ExXy4kkKZJ4BOcmaABujhHzlZbhlkmwdHiUWyEJcKOXQIpnTrqBKsQA59V6CnmqnxWiqv
/osu8ZT92OeGIqv8jLj8yt7dk/aLU9odlFGOu/bQL3Owhj08ARqgARprCegLq6FeWHoF0PfpoYkG
BtBEAwnxAh2QkECiAxISSHQAaKKBdQ+0KmxkuaZweFoADdAFdo5+4ZFtcUtklyYpATQ9dHWNlH/L
UWu8AWiArg9ovx/WGmcAuj+gZdbXH76pp8l3aU1gyGoIo63c7PmXtcXb1m3VDD6A7g7oabZnyDeK
cKoFsyMDzbac8OJJTuVdsLgovF8Pncx7Dl49ivKKk2lgQSoVurweaHLoWwOdlAVGPW5SPBjSUsLX
Ap1v6wbQAD1XXOXsCF7alPAlQOdJO0ADdFr8N+TTylKOvJTQ3Tb2yrYwygHQw0WT4oK/dF82ezi+
zjJFg2bEY+caSLtaUqwpHHaMY5TjXj000cAAmmhgAE00kJBAogMSEkh0uJuEb8L+2htA0iegBEYY
UYIwogRGGFECI4wogRFGlMAII0oQRpTACCNKYIQRJTDCiBKEEUMJwogSGGFECYwwogRGGFGCMKIE
RhhRAiOMKIERRpTACCNKEEaUwAgjSmCEESUwwogSGGFECcKIEhhhRAmMMKIERhhRAiOMKEEYUQIj
jCiBEUaUwAgjSmCEESUII0pghBElMMKIEhhhRAmMMKIEYUQJjDCiBEYYUQIjjCiBEUaUIIwogRFG
lMAII0pghBElCCOGEoQRJTDCWKf9/Pj40J+fn0gB0D3Y72/6a99+IwVAd2E/PoH+gRAA3VEXTQcN
0F110XTQAN1TF00HDdBdddF00ADdUxf9RgcN0Nfauxq2dzS9RC3xx3dr57tzC6AhB6ARH3IAGqBx
C6ABGrcAGucBGiYgB6ARH6ABGqBxC6BTX79uJ21tn5baqzuT42m6UmSAft5Xbff9b3BmA6RbA+1o
qpf5fU+g4wNa0bQDemj1DnR+AKABGqABer/4n4nCV/r3lfLJHIpSwQfQfx+NyaHCdGL84vFF41OP
B+obaAWjgSPA9GB6aP4D6KfE1/T7QHN8yD5nf6bIlX+iP4LhYb9AD0R6Oih9oEyjAxt5Q6BNpzrQ
a2EOMbg+0GOnPL1AFnJ7bu8ph8KcHqk4CvHLdZJbN0o5nF46eED/TR/sQbl5o0my5Z3bfQ5d1MN7
QkksBNCXAK384GqgnQwEoAtAk3IcAPQEs5KU7uvAmPXlWYSNU4F6pSlH5xeFYfaio3CBQQ79rK/x
TS2ZsQ4zPmGOxKMbit7IjmyEeAAkZOfu/1ZVK5pGw0Uyv88MAVnhAPpyX9Wy87gF0BU0GqAB+iRf
XzPhBqABumVfARqgARq3ABrncQugcR6gER9yAPqqVl5ZKST3gbolRwsHtPW9BdBLvl5ZKeT/6ahb
oLOWJQdmWv5MLwPQlzvhT2+ihz6myQAN0ADdMtAqzaHxCoWKlUJ23k3IptukpUbD5OgQFXhFRQXz
JeX1A53O7Rqn5k7l8sPs8EyP6RVTquHrv6pa64az7YI3w9EtFCrOclRWZDVTeBXPJR0Td68QrFmg
3Tmh2fRRlfWYJjxOiFtRo8m4AJ0XeTuVQl6hULFSSHkOobG7T/40pjdPM40p0rPdTgNAj41OJ/bL
b6qpcQuO4JHIyuovADoHOh/lcI8XK4VUKsmYqcwoA916Dj1fxeM0dTXQY6ISdRwAfRjQyW/3BPpX
GegVPfQ2oGW+DbVGj/sC7dX8LaxI4OfQ5lT/zCnVDqbASw3m0B/f/92UQ48pmJKqYcl2DX5xp3Mx
AtDZRWE+yuEXCpUqhbzDs6VG8VV99Jn2wxsBWvpEemmUYyzLWjnKYVfxUVrGtkqqwFwOnN8B9CfS
zOWAiZ3OV2nfARqg++mh9c8vgIaJboD+5xfTR2GiG6D/4gzQMNGJ8//5VbWmAI3zuAXQOA/Q9bZS
dberIXLMbY8NVWYHhgCgk+kuAujdbvn38NdUmR0XAoBe6B5eX+zSFtDOL0/20NokDEADNEA3DbTZ
8CqZNZQ8M9RJmRqr6DhAmyxBkUJzVWZ5ndtcCIb38KaQCaCdDa9k5yxKbj3VcVtMdAi0sk05ZqrM
nDq32RBEU/dCPm2XHjpD1kwudeeim4oVXd38RipW5GUahSozeRPRSyGw1RFyyufvnnKEAtDTM0nd
j53RC9A7gA5ZBFaHwBYYArSbcnhq5oeK294A9BNAl0qFSiFQ+o4AnYgvvzZKXvn8uEnWcbta3SKH
nqkyU76b6WwITKetdLMygH5cOCutERr3qkpLqkxVVXSNTQ9dGuWYrzLLthZbCIGt6jJP00O3aMzl
uMYtgIYcgEZ8yAFogMYtgAZo3AJonAdomIAcgEZ8gAboQ1o5DdmnVRJ2+bqKClfUqqb5TWoB9PGt
dOdipFPrVFH71Kim0azQC3uJW862mwXamdII0Hs0HedapP8D9MG9SY6r+bIE6EM0Bejrvh7jDVCk
tHsB6GM0Vf6NB9An5Xuutk4eDdD7NS3shgDQFwNtp5MD9F5N3c4ZoM+6IleecqSlKgD9lKaDtOn/
AH2K+N4IUmlLLIDerSnj0JeJ7+9ErdmcBKD3aArQp7Zy/N5zh+2mr0XuFD6rKUDfj4lueugu3AJo
yAFoxIccgAZo3AJogMatfiF5U8P2hqaXqNV0r0f/jxFGlCCMKIERRpTACCNKYIQRJTDCiBKEESUw
wogSGGFECYwwogRGGFGCMKIERhhRAiOMKIERRpQgjBhKEEaUwAgjSmCEESUwwogShBElMMKIEhhh
RAmMMKIERhhRgjCiBEYYUQIjjCiBEUaUwAgjShBGlMAII0pghBElMMKIEhhhRAnCiBIYYUQJjDCi
BEYYUQIjjChBGFECI4wogRFGlMAII0pghBElCCNKYIQRJTDCiBIYYUQJwogEKEEYe7OfHx8f+vPz
EykAugf7/U1/7dtvpADoLuzHJ9A/EAKgO+qi6aABuqsumg4aoHvqoumgAbqrLpoOGqB76qLf6KAB
+lp7V8P2jqaXqCX++G7tfHduATTkADTiQw5AAzRuATRA4xZA4zxAwwTkADTiAzRAAzRuAXTq69ft
pORZ6XAJtfBidUTOCZoC9Hpflfqu5xqzKXJ7wqz7aQrQG8XPDxzx5jpHNd1QU4AGaIC+fcrxled9
5X+PnE8hezA9NP9NCUT0svjc6YnxlD//yXgh9QP0QZoC9GbxR7zyn0c4ogeaHo7/RVDqgbVC+kbT
+enx4U9hfL4DoA/TFKD39CaaLs4HraPf7RPjyY+jyr5nlVwFKYtqdKaSPq0ToI/SFKCf+HqUc0Xu
PSH7HtIs0I+0Qjm0fQN9jKYAfb34GaAqfNcC9HZNAfqJK/Iie2kSuJRDT+dpzJM1l1B2CfQxmgL0
Rl/HXE7eFbm56P77r7laj18Sf1NGgxiPk8Zz7TnTKId9vnGgD9UUoHvztcUeugu3ABpyABrxIQeg
ARq3ABqgcQugcR6gYQJyABrxARqgARq3ADr31dzqa6EdrZKjhQPp88fcL7wd0GbajA6d6HUPoP/5
d51b0vwBOXwLoHcBnYmomttXmdD/o+//ntFD65i2AjRAbwVan0gDdBVM6DEdLiSFQdOkr8eEMKmS
ZOT//m5UW5F9/5Tm+7/ZdUk2k87kdEPhg1NeOU3QM7P09mWD9+yh107ZrcH+98D9Gv77HKDdSc6Z
uEmJpTszfHqwtz8B6KzsLaiu0Q/V9VZOyjEVDKaVKjnUeXll9G2ZlWAC9JM99KHpXK9AZxeFcoVz
gfZep7yHDgB9IND00HPmDNvJFW4l0G7KAdCbgU5WzXCW0KilharyrcLaHHpcvkC2ID5aykNpWWYg
5dg0yjF8zUXX5SEd5ajnjkv9QLujHLHQc6McUxXmiLYUuCjsxtcWge5CLYAGaIAGaIAGaIAGaIAG
aIAGaIAGaIAGaIAGaIAG6MNaOS0UqHSGjV19EaCfe6/yDAI/BNEqj7tDcM8e2pkuMG2pUFvLmgV6
lkl3xoayfwF6HdAlzWqsmm27h16gXcUTAHpTD+13xTV20L0C7YgdJxoKAL0p5Yiqr5Rs4lRZIXgL
s+2yNcyTzWZk9xRaCAFA78mhVeihpcraVj3Q2f5WZm87Z3+7uRA8OR0aoP2Mg1GObT206X21tJPS
CqAVAHrrKIey7zuAfgbo6WpvLdBOCAB6P9DO2j4A/TTQcc/r1SEvhACgnwC6sPIJOfRuoGUqqry9
oRdTZb0My6bvFEploBnl2HVRaCrYQlrlNt0BnAlBmncAdA++NthDbzpDtaoF0AAN0AB9Y6DDFQsG
AjRAd6UpQAM0QAM0QAM0QAM0QAM0QAM0QF+hw5uqtLdbQFKp+GeHqK8/bHo9lCBmiAPQhBEl8JQw
ogSeIg5KEDPEQQlihjgATRhRAk8JI0rgKeKgBDFDHJQgZogD0IQRJfCUMKIEniIOShAzxAFoDHEA
mjCiBJ4SRpTAU8RBCWKGOACNIQ5AR/ZeZ438O0ADdE+tFkADNEADNEADNEADNEADNEADNEADNEAD
NEBjAA3QAA3QAA3QdQOtr31jK9AKoAH6+fd6bIW84iSABuj6gd6wRSxAA3QrQAeABuheUg5FufT0
3+O4wvRQ0Ys+Hz9+ABqga7ooHNH9/JH59ZPX4WH8a3wKQAN0VUAPF4YjvcMrZDAPUc89Zd4ADdD1
AR0SkstAD5nH8CoFgAboKkc5VgEt2y8DNEBXB3TMqEq/DomzTMpx9Ng0QAP0AT30NKyRj3JMAxkD
zeP4xgnyATRAv/i9ABqgewJaAaABuhugD5/cAdAA3VWrARqgARqgARqgARqgARqgARqgAfqlQB86
G9SdMjL3PEAD9Db7tfBex06fy/44pIXnARqgN9nH938XgaaHBuh2gJY+kQZogO4F6E+kk8lJYZyA
FP0eHY8LsZT/F6Lzg8xpjzcZMoyoiCs4iycA9J2AfjtupfzvSq4C8x9zPC7EspOkZXNvf95pMHQH
U9MF0LcF+gj77KH1z690gv+j/CorxTLHJ7VstVb0umDqWQpQR28P0AD9NND//MorVpSPcrjHk1nQ
UqZi8bS45iUANEAfBPRfnA8DOj+woocG6NPs58fHh/78/LxNi//zK4u/gptDF4/vyKHHtEVRia2c
uzgA/Zz9/vaZ0H37fePvJTNeEY1ypMej38zhuVGOuHaLUY4r7Mcn0D9ItJp3C6CnLvqGHTRA99xF
37CDBuiOu+g7dtAA3XEXfccOGqD77aLffgM0QF9q72rY3gEaoHv6NhFuATRA4xZA4/w+t6Zbf7L7
VAigAbrJrtBbR1SvcR2gcf4AoOUD/QLfARrnj+ihC/gCNEA3mnJM0zkVJdMADdCt5tBartAGaIBu
GmhGOc5vpZLBpX2tuHREqpVRDqUphwJAX9ebPPt2Auj093SVrgDQF/Ym7SDW8Dg0F4UA3SDQ0Yoa
Ni17xb3C+wKtaBGeabGpeN0qRbvp5atdzS13lW3Xp56B7sStxnPosZx4qDFORlNtruws/jOz3JW/
oSrkAPQpQJvvx3yRqugCPVszJb58n1nuyq52dcQlKEAD9MIFTAFoyd9YPVsEaG51oGwtIEEOQL8E
6Gy9qkOAJuUA6NcBbbIEZQwnObS73BU5NEBfP8RkFp6yPyGbXOOsdjW33FVpTW/IAejXtlKQA9Ad
tVKQU7S3Omvk3wC6fJYCQN/HmD6K8wCNrwCNzgCNoTNAYwCN8wDdmq9a0ZTCPjR6RgaWeQXoq3zN
NlLS7NPrn6SHBuiX+Lqyh3ZPA2iABmiABugjc2gFWxs1VKw8phKVtsIzp4478oVsBlJSrhVMIYCd
EAXQAP2cr4oqpYqbnCp7mJ069dCm6mpC23nPwqRrgAbop3voUNpPeuqxo37VOdWkHLKLI3tVWUOv
L4AG6JcA7aTJs0AXc2uFpOD265AuGPDDABqgAbptoL1VCKJKWQVbvpJymebFKegZ0NPiCYxyAPQR
F4XxEIP9N8yPcmSjE/GQRTRmkRZeJTVaIWxcHA+gAborJgAanQEaA2icB2h8xXmAxleARmeAxtAZ
oDGAxnmAbsjXwkbr8YwiITRAN+Sru8epkmXOERqgmwHax1bVNgyg0Xm+h9Ys0EJogG4s5fA2Wgdo
gG43hxY9NHYToIXQAN0c0PlG6wAN0C0DnReMADRAtwx0KeUQQgN0S776G63b4iiEBmh8xXmAxleA
RmeAxtAZoDGAxnmAxlecR2d8BWh0BmgMoBEaA2icB2h8xXl0xleARmeAxu6o85satjdYA2iUwAgj
ShBGDCUII0pghBElMMKIEhhhRAnCiBIYYUQJjDCiBEYYUQIjjChBGFECI4wogRFGlMAII0pghBEl
CCNKYIQRJTDCiBIYYUQJjDCiBGFECYwwogRGGFECI4wogRFGlCCMFdj7uYvP/dep7/4OagDdUxdK
/4/QAI0BNM4DNK7iPEDjKkAjNEBjCA3QGEDjPEDjKs4DNK4CNEIDNIbQAI0BNM4DNK7iPELjKkAj
NEBjAI3OGEDjPEDjKs4j9Hn28+PjQ39+fraocdPOA/Qp9vvbZ6npt98taty08wB9jv34ZOJHmyI3
7TxAn9fLtdrHNe08QJ/XyzXbx/2ggwbovJdrt49r2nmAPquXa7iP+0EHDdBpL/fWcB/XtPP3Bvrk
FejOXXiuaeexU4BWyyKICAI0QAM0QAM0QAM0QAM0QAM0QAM0QAM0QAM0QAM0QAM0QAP0a4D+upMV
P/rz7HiHq/z5mn+sOdd1FNDW+R3vmZ8sgG69h9Z0QF9RHg9pBoXZx7OU6TCgl7xc8ZY6wjeArg3o
6J+//y0DvbaHdk87GOjl99P6wwDdD9A2TdA2nwAaoGtLOVTMs7+6bcV5p76+nmWylPEl5o9D0xf5
V8qbvtchKcfXe02fNbgpDZ8aXypMzoTMcX2dEjV1eqAn8yXsAqDHcBZeM4YzzkSSn+TpmKrx1DhL
X5PVrAI6dl7RZymEGMnhQAjRr0r+KgbHo5dPJMeHALryHnoe6AzgFIKxxzY8Zadm+c2mMQotOK8U
5qRlKudY0d+YhXtkOfkUgO4h5VgG2klr54E+cJQj+fAc6CjvyYB+pBrRk841xTMDKgD9CqANFP0B
nTuYODkPtElaALqJYbscDR9o+7U8/p8e9oGW/wfy7ChHksvbhFfT5xZyaCUJc+YiOXQjQI+Jor3w
j5PF4ao/vs4fT5of5bCnRleJ28cMtOC8O8ohyVyb+qMcXw7FjpuBE/tOjHLU3kO3JoIabBlAAzRA
AzRASwJogO6oh75LBAEaoAEaoAEaoAEaoAEaoAEaoA9+w3SK5Tke6BygZ52f/fSlGqxjaskA+nKg
x7uFp2qvc4De73zm0Dm1ZAD9EqAvKOE4D+idzq/toVd/JEADNEAD9IFvOOSfQ6mSnYcjM58uK0yK
ZyTZ6Ub+y5y5SSun/Wi/8/IKwrxSsr21ZIvZO0BfB7QzGThkczwLhUlK50XbWdH+y/JT7JlbgF7l
/OTTgkN7a8mWs3eAvhDotHAqPhDmC5PSOqW09wy2itVjKP24jUCvcN6f2O1VIOytJVsuzALoa3vo
4K7OkT9RKvOYLvmVlDXFnbzsGyUDE6u/tbc7r61AO2nyLNDk0B0C7ZQ7yc8BgvyqJp0EdLluDKBv
mUMrA9onNc2hk8xbSfZxTQ6tAr1eKdneWjJy6IZGOYLs8hbx2IQZ9HAGOaL6q+hh8kZrq7H0pPMh
KQjzSsn21pIxylET0I00iLkcAF2rvgeubQfQAP1qfXfO5wBogO5KX4AGaIAGaIAGaIAGaIAGaIAG
aIA+/g2nGxFS1TFYA/T2dWbWvX5eJDE5qaoe2t27rb4liFYAvb0Ia3UrZ0RasyUNQF8JtB+RRoHe
6L22kV8WCaAr6qEF0MuvmxeJuRxVpRzxRHWZCUS1A53UcimZrhTSja7czbyc6Upp0rUkEkDXlUOr
0R66WE6VbjuRVISVy8HkK7IkEkAD9EFARzlutLOWs9NVUhGWlYTZrQvkXm+WRFIA6LpGOdRsyvH4
V3mPHJfGZC9xSsKk7E9krUgAXRvQzhJCjVwU+psQpUDP7HsUvUzFC8sFkQC6OqAbz6Hz/CHbm1DO
5rdJte58Dl0WSQGgawG6lGJUd2eltIxBiMu9orGKNMc2FWFeSVhavLVBJICuqYduTQQd31A1F0GA
viXQtfAM0AB9ANDSkS8DaIB+fcrRbQQBGqABGqABGqABGqABGqABGqABGqABGqABGqABGqABGqAB
GqABGqD32Jvas7cunMf4+0ZnhMbQGaExdEZodMYQGp0RGkNnhMbQGaHRGUNodMYQGp0RGkNnhMbQ
GaHRGUNodMYQGp0RGkNnhMbQGaHRGUNodMYQGp0RGkNnhMbQGaHRGUNodMYQGp0RGkNnhMbQGaGr
sPfTVqD7r/MWt3snbgDdkxqEEDUAmhCiBk6jBmrgNGqgBiFEDYDGUAOgCSFq4DRqoAZOowZqEELU
AGhCiAE0IUQNnEYN1MBp1EANQogaAE0IMYAmhKiB06iBGjiNGqhBCFFjk/38+PjQn5+fOA3QPdjv
b5811N9+4zRAd2E/Ptn4gdMA3VEX3Vpf16TTAH1db/cDpwG6oy66vb6uSacB+qre7gdOA3RHXfTb
b5wG6BfbeQssnrmEYpteA/R9W6AevQYHgAZoWgDQiEkLABocaAFAgwMtAGhwAGiApgUAjZi0AKDB
oZ8WfN3tih/9eXa8C7bUbK18rAuBXt8i7x21cEAAXXsLNB3QFwLjIS2ys+3xRT30gS1KDwigmwA6
+ufvf2vDv7qHvh7oo1pED90u0DY/0B4pKgP6gBYBdLsph5tfTmnn1+seDx+H9fUlrPibfTxleJye
ewDQkR/28YoWFZrktWhMVvIWAXS9QI/hcl6jiOxHYONv7+RH3uP03AOAjv1QyN57tkWFJnktGunO
WwTQVffQs0Cn/V76XR6BNdAlJV3kuhR2Sw+dfKblfa5FhSap1Er5LQLoZlOOzUCnV2bXAf3omhdT
jq1AOy0C6PqBtl2YMg7qB3pli4ruA3RXoxzpUFeYD7XtGc3/5viJQHt/SEstKjTJa9Hwi9cigK60
BcPts/FSX8nheGxg+AnJv2FhlMOee8xFYeJ29Mcz36JSk7wWMcpBC050i7kctACgwYEWADQ40AKA
BgdaANC0AKARkxYANDjQAoAGh1ZbsNwiSeertO1O4fZP3N4IgG6yBVpVx7Fxsv6pQO/6RJ0TO4Cu
qwWbC5N0mkr7gdaaT9Q5MQRogAZogD6rBWOZf5plJpOQZH5PZwN9vWley+TNZSqnsltn28WzjJQ5
4DdinIm0aroUQDfaQyub4VkuTPImPi/UMplnypVYG2bbJWVXClMrZhsxM+kUHPpKOaLqKfMSpU96
E5DtX4PcvwFTyXRID50CHeKCKb8RWTkVQHcNdDZo4KzRMtZZR6+0fxVxf5ggPjsccRDQc41IyxcE
DncB2s0fPBby3CIHOiFNVwHtpxwA3TfQ8rgd008nf5DpZ5PXyPTHUjghh3aAVvYX5TZiepFmvywA
ul2g88oqOz7w9aSiQYo0P1X8JtHDOHtOxxyevCjMBlpCWkxVaIQp3ToklADdRwt0/CddP5cDoGnB
eTxfD7TAgRaE9bnn1gz1YqAPmqoEDrSgmpQDHGgBQIMDLQBocABogKYFAI2YN2/BdM8j2x5HrQG9
ciix2OJ98QXoylogt1WqT9jNO1gtvJH/BywBdONAz6x232MPXbzvTQ/dSw+tuwHtl2wBdDcpRzw1
3tZk1Qr0UGuwq+rLazFAd5VDy0lDVDHQA837qr7cidMA3TXQL2nnppRD2l31BdD9j3IoTTkqB1oy
XfO2qi+vxQDdF9B+yCtPOfZWfXktBujOgPZL8SoG2m4mu6nqyx95B+guWpB94bpf0tUB/Sip2lP1
VW7xvjsrAE0LjrgorKZx4EALzgRaiEkL+gFaQkxa0FfKgZi0AKDBgRYANDjQAoCmBQAN0LQAoMGB
FgA0ONACgAYHWgDQtACgAZoWFOxNVdpbj14DNIYBNIYBNIYBNAbQGAbQGAbQGAbQGEBjGEBjGEBj
GEBjGEBjAI1hAI1hAI1hAI1hAI0BNIYBNIYBNIYBNIYBNAbQGAbQGAbQGAbQGAbQGEBjGEBjGEBj
GEBjGEBjAI1hAI1hAI1hAI1hAI0BNIYBNIYBNIYBNIYBNAbQGAbQGAbQGAbQGEBjGEBjGEBjGEBj
GEBjAI1hAI1hAI1hAI1hAI0BNIYBNIYBNIYBNIYBNAbQGAbQGAbQGAbQGAbQGEBjGEBj2Gvs/wF1
UpjdFN/2BAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-03-27 15:46:54 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-03-27 15:39:41 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-03-27 15:39:29 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Substance-related disorders*:ME<BR/>2. ((opioid) next (addict* or dependen* or abuse*)).ti,ab<BR/>3. #1 or #2<BR/>4. Heroin:MESH<BR/>5. (opioid* or opiate*)<BR/>6. Methadone:MESH<BR/>7. #4 or #5 or #6<BR/>8. NARCOTIC ANTAGONISTS:ME<BR/>9. Naltrexone:MESH<BR/>10. Naltrexone:ti,ab,kw<BR/>11. (sustain* next naltrexone):TI,AB,KW<BR/>12. delayed-action preparations<BR/>13. #8 or #9 or #10 or #11 or #12<BR/>14. #3 and #7 and #13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-03-27 15:43:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-03-27 15:43:37 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>1 naltrexone/<BR/>2 naltrexon$.tw.<BR/>3 or / 1-2<BR/>4 exp Delayed-Action Preparations/<BR/>5 implant$.tw.<BR/>6 depot$.tw.<BR/>7 ((sustain$ or time$ or controlle$ or delay$ or slow or prolonge$ or extend$) adj2 release$).tw.<BR/>8 ((prolonge$ or delay$) adj2 action$).tw.<BR/>9 or / 4-8<BR/>10 3 and 9<BR/>11 animals/ not humans/<BR/>12 10 not 11</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-03-27 15:44:24 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-03-27 15:44:11 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Naltrexone/<BR/>2. naltrexone.tw.<BR/>3. or / 1-2<BR/>4. exp controlled release formulation/<BR/>5. exp controlled drug release/<BR/>6. exp sustained release preparation/<BR/>7. implant$.tw.<BR/>8. depot$.tw.<BR/>9. ((sustain$ or time$ or controlle$ or delay$ or slow or prolonge$ or extend$) adj2 release$).tw.<BR/>10. ((prolonge$ or delay$) adj2 action$).tw.<BR/>11. or/4-10<BR/>12. 3 and 11<BR/>13. (animals/ or animal experiment/) not humans/<BR/>14. 12 not 13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-03-27 15:44:55 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-03-27 15:44:44 +0100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:44:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Naltrexone/<BR/>2. naltrexone.tw.<BR/>3. or / 1-2<BR/>4. Delayed-Action Preparations/<BR/>5. Drug Implants/<BR/>6. implant$.tw.<BR/>7. depot$.tw.<BR/>8. ((sustain$ or time$ or controlle$ or delay$ or slow or prolonge$ or extend$) adj2 release$).tw.<BR/>9. ((prolonge$ or delay$) adj2 action$).tw.<BR/>10. or / 4-9<BR/>11. 3 and 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-03-27 15:45:36 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-03-27 15:45:23 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:45:36 +0100" MODIFIED_BY="[Empty name]">
<P>basic search form: naltrexone</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2008-03-27 15:46:12 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-03-27 15:45:56 +0100" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. naltrexone/<BR/>2. naltrexone.tw.<BR/>3. or / 1-2<BR/>4. implant$.tw.<BR/>5. depot$.tw.<BR/>6. ((sustain$ or time$ or controlle$ or delay$ or slow or prolonge$ or extend$) adj2 release$).tw.<BR/>7. ((prolonge$ or delay$) adj2 action$).tw.<BR/>8. or / 4-7<BR/>9. 3 and 8<BR/>10. animals/<BR/>11. 9 not 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2008-03-27 15:46:54 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2008-03-27 15:46:34 +0100" MODIFIED_BY="[Empty name]">ISI Web of Science search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-27 15:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>#6 #5 AND #1<BR/>DocType=All document types; Language=All languages; Databases=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1975-2007<BR/>#5 #4 OR #3 OR #2<BR/>DocType=All document types; Language=All languages; Databases=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1975-2007<BR/>#4 TS=((depot* or implant*))<BR/>DocType=All document types; Language=All languages; Databases=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1975-2007<BR/>#3 TS=((prolonge* or delay*) SAME action*)<BR/>DocType=All document types; Language=All languages; Databases=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1975-2007<BR/>#2 TS=((sustain* or time* or controlle* or delay* or slow or prolonge* or extend*) SAME release*)<BR/>DocType=All document types; Language=All languages; Databases=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1975-2007<BR/>#1 TS=(naltrexone*)<BR/>DocType=All document types; Language=All languages; Databases=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1975-2007</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>